
==== Front
MoleculesMoleculesmoleculesMolecules : A Journal of Synthetic Chemistry and Natural Product Chemistry1420-3049MDPI 10.3390/molecules23020283molecules-23-00283ReviewPeptides as Potential Therapeutics for Alzheimer’s Disease Ribarič Samo Institute of Pathophysiology, Faculty of Medicine, Zaloška 4, SI-1000 Ljubljana, Slovenia; samo.ribaric@mf.uni-lj.si; Tel.: +386-(0)1-543-702030 1 2018 2 2018 23 2 28315 1 2018 28 1 2018 © 2018 by the author.2018Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Intracellular synthesis, folding, trafficking and degradation of proteins are controlled and integrated by proteostasis. The frequency of protein misfolding disorders in the human population, e.g., in Alzheimer’s disease (AD), is increasing due to the aging population. AD treatment options are limited to symptomatic interventions that at best slow-down disease progression. The key biochemical change in AD is the excessive accumulation of per-se non-toxic and soluble amyloid peptides (Aβ(1-37/44), in the intracellular and extracellular space, that alters proteostasis and triggers Aβ modification (e.g., by reactive oxygen species (ROS)) into toxic intermediate, misfolded soluble Aβ peptides, Aβ dimers and Aβ oligomers. The toxic intermediate Aβ products aggregate into progressively less toxic and less soluble protofibrils, fibrils and senile plaques. This review focuses on peptides that inhibit toxic Aβ oligomerization, Aβ aggregation into fibrils, or stabilize Aβ peptides in non-toxic oligomers, and discusses their potential for AD treatment.

aggregationAlzheimer’s diseaseamyloid β oligomersamyloid β peptideamyloid β plaquesinsulinneurofibrillary tanglestau proteinpeptidespeptide therapy
==== Body
1. The Social and Economic Relevance of Alzheimer’s Disease
The increase in life expectancy is accompanied with an increased number of patients suffering from Alzheimer’s disease (AD). Patients with AD experience a progressive memory loss combined with a decline in cognitive function and ultimately a premature death 3–9 years after diagnosis [1]. AD is the most common cause of dementia, with a prevalence that increases with age to about 50% in people aged 85 or older. In practical terms, the majority of the population will have AD provided he or she has a sufficiently long life. The worldwide number of patients with AD is projected to increase to more than 140 million in 2050 [2].The total estimated worldwide cost of dementia in 2015 was US $818 billion, will reach US $1 trillion in 2018 and US $2 trillion by 2030. The true number of patients and the associated cost of dementia are likely to be considerably higher, since a huge majority of people with dementia have not received a diagnosis, have not been registered, and are thus unable to access care and treatment [3].

2. Etiology of AD
The characteristic changes in the brain tissue of AD patients are: (a) hyperphosphorylated tau protein rich intra-neuronal neurofibrillary tangles (NFT); (b) extracellular senile plaques of aggregated amyloid β (Aβ) peptides; and (c) brain tissue atrophy, starting in the entorhinal region and the temporal lobe, and progressing to the limbic system and the neocortex [4,5,6,7,8,9]. Most patients with AD have a sporadic, late onset form, where the major risk factors are aging, type 2 diabetes (T2D) and apolipoprotein E ε4 (APOE-ε4) [10,11,12,13,14,15]. A minority of AD patients have an early onset, genetic, familial form of AD due to autosomal dominant mutations in amyloid β precursor protein (AβPP), presenilin-1 (PS1), and presenilin-2 (PS2) [16]. The initiating step that leads to the disease in most AD patients is not known. The number and extent of amyloid plaques have only a week correlation with the degree of cognitive decline; they can also be found in individuals with mild cognitive impairment and in people with no cognitive symptoms [17]. There are at least three possible, and non-excluding, explanations for the lack of correlation between Aβ plaques and cognitive impairment in patients with AD: (a) person-to-person differences in the ability of inflammatory cells to effectively remove senile plaques from the brain [18]; (b) the high neurotoxic properties of Aβ42 oligomers, which precede the less neurotoxic senile plaques, are the main cause of cognitive impairment; and (c) person-to-person variations in brain plasticity, the ability to restore brain function after injury that operates over long [19] and short [20] timescales.

2.1. Amyloid Precursor Protein (APP)
The human amyloid precursor protein (APP) is a single-pass transmembrane protein in nerve cells. The physiological significance of APP is not fully understood, although it has a fast turnover rate in the mature, normal CNS [21,22]. APP is first processed in the endoplasmic reticulum and Golgi apparatus, and then transported either to synaptic terminals where it is inserted into the synaptic cell membrane [23] or into endosomes. The cell-membrane bound APP is processed by three competing pathways: (a) two amyloidogenic pathways; and (b) a non-amyloidogenic pathway (Figure 1). In the amyloidogenic pathways, APP is: (i) either sequentially cleaved by β- and γ-secretase leading to direct extracellular production of amyloid β-peptides (Aβps); or (ii) re-internalized into endosomes containing the β- and γ-secretases, leading to intracellular production of Aβps, that are either exported to the extracellular space (via vesicular transport) or degraded in lysosomes [21]. The APP re-internalization pathway substantially contributes to production of Aβps since: (a) β-secretase is located predominantly in endosomes [24]; and (b) 80% of Aβp release into the extracellular space is blocked by inhibiting endocytosis [23]. The amyloidogenic pathway first proteolyses APP with β-secretase into a soluble APPβ peptide and a 99-amino acid membrane bound C-terminal fragment (99-CTF)—and then proteolyses the 99-CTF with γ-secretase into a APP intracellular domain fragment (APP-ICD) and Aβps with 37–44 amino acid residues [21]. Low concentrations of Aβps are present in the central nervous system of non-demented individuals, therefore, Aβps could present a negative feedback loop in the regulation of synaptic plasticity and neuronal survival [25]. For example, the Aβ(1-42) monomer’s neuroprotective role is mediated by activation of the phosphatidylinositol-3-kinase pathway, and the stimulation of receptors of the insulin superfamily [26]. APP is cleaved by α- and then γ-secretase in the non-amyloidogenic pathway; γ-secretase activity is present on the cell surface and in endosomes [27,28] while α-secretase proteolysis of APP occurs mainly on the cell surface, and to a small extent in the Golgi apparatus [21]. APPα, the soluble product of α-secretase action on APP, has neuroprotective and memory-enhancing effects [29,30]. In physiological conditions, APP is preferentially processed by the non-amyloidogenic pathway and increased Aβp production correlates with decreased sAPPα levels [31,32,33,34]. Amyloid processing of APP is concentrated in lipid rafts, and non-amyloid processing in the non-raft regions of the cell membrane [35,36,37,38,39]. Proteolytic enzymes of both APP processing pathways are modulated by external factors. For example, some metalloproteases have an α secretase activity, contributing to the production of soluble sAPPα [40]. The amyloidogenic pathway activity is attenuated by cholesterol lowering drugs, metal chelators, steroid hormones or non-steroidal anti-inflammatory drugs [41]. Decreased cellular cholesterol levels disrupt the lipid raft’s structure and function, leading to a concomitant decrease in Aβp and an increase in sAPPα formation [42,43].

2.2. Pathological Processing of Soluble Amyloid β-Peptides (Aβps)
Aβ peptides are useful for neurons [26,44]. The key biochemical change in AD is the excessive accumulation of per-se non-toxic and soluble amyloid peptides (Aβ(1-37/44), in the intracellular and extracellular spaces, that alters proteostasis and triggers Aβ modification (e.g., by reactive oxygen species—ROS) into toxic intermediate Aβp products, misfolded soluble Aβps, Aβ dimers and Aβ oligomers. For example, intracellular accumulation of Aβ(1-42) per-se promotes increased ROS production and p53 mediated apoptosis [45,46,47,48]. The toxic intermediate Aβp products further aggregate into progressively less toxic and less soluble protofibrils, fibrils and finally extracellular brain senile plaques composed of proteinaceous deposit with β sheet structure. The most common Aβ is Aβ(1-40); Aβ(1-42) is the most susceptible to toxic conformational changes leading to nerve death and amyloid plaque formation. Aβ(1-42) monomers with intermediate conformations and Aβ(1-42) oligomers are the most neurotoxic and amyloid plaques the least [49,50]. Modified Aβ(1-42) peptides enter the cells via endocytosis and lead to lysosomal fusion dysfunction. The overall effect of lysosomal fusion dysfunction is an enhanced transport of vesicles by the exosomal pathway with increased shedding of modified Aβps into the extracellular space and a reduced Aβp digestion rate by macroautophagy [51]. Aβ(1-42) oligomers interfere with synaptic transmission by: (a) promoting neuronal death by attenuating NMDAR desensitization thus increasing the probability of intracellular Ca2+ overload [52,53]; (b) decreasing the density of AMPA synaptic receptors [54]; (c) uncoupling metabotropic glutamate receptors’ (mGluR5) dependent activation of PKC [55]; and (d) reducing glutamate reuptake thus promoting an increased NMDAR and mGluR5 mediated entry of Ca2+ [56]. AD studies on patients and animal models associated Aβ oligomers with synaptic dysfunction, cognitive decline, inhibition of hippocampal long-term potentiation (LTP) component in memory, and learning and memory impairment [57,58,59,60,61,62,63,64,65,66]. Aβ oligomers were better correlated with dementia and synaptic loss then Aβps in amyloid plaques [57,58].

2.3. Factors Promoting and/or Sustaining Pathological Processing of Amyloid β-Peptides (Aβps)
2.3.1. Aβp Oxidation
Aβp oxidation promotes toxic misfolded Aβ monomers, oligomers and intermediate products [67]. For example, oxidation of Aβ(1-42) at the methionine residue 35, Aβ1-42-MET35-OX, promoted by H2O2 or copper ions, accelerates the production of toxic Aβ(1-42) products directly and indirectly by increasing oxidative stress, protein oxidation and lipid peroxidation [67,68]. In a cell model, ROS stabilize Aβ oligomers, by dityrosine cross-links in Aβ(1-42), and promote internalization of toxic Aβps into lysosomes [68]. Dityrosine crosslinked Aβ oligomers self-assemble to form amyloid fibrils; their presence was detected within plaques in brain samples of patients with AD [68].

2.3.2. Mitochondrial (MITO) Dysfunction
Aβps and Aβ oligomers accumulate in MITO samples from transgenic mice overexpressing mutant AβPP and in post-mortem brains and from AD patients [69,70,71,72]. In human and animal studies, increased Aβp levels either preceded or followed MITO dysfunction implying a positive feedback loop. MITO dysfunction was due to: (a) oxidative modifications of key MITO enzymes (e.g., pyruvate dehydrogenase, isocitrate dehydrogenase, α-ketoglutarate dehydrogenase and cytochrome c oxidase) [70,72,73,74,75,76]; (b) reduced antioxidant defenses [77]; and (c) increased production of ROS [78]. Human and animal studies are in agreement that Aβp binds with MITO Aβ-binding alcohol dehydrogenase (ABAD) precipitating increased ROS generation, MITO dysfunction and cell death [79]. MITO dysfunction can also stimulate the amyloidogenic APP pathway; in a transgenic AD mouse model, knockout of manganese superoxide dismutase, a major MITO antioxidant enzyme, increased Aβp levels and amyloid plaque formation in the brain [77].

2.3.3. Oxidative Stress
In AD, oxidative stress supports a self-sustained process of increased production of soluble Aβ oligomers from Aβs with a concomitant progressive failure of macroautophagy (reduced clearance of Aβs) and mitochondrial function (increased production of ROS). Oxidative stress upregulates β-secretase and γ-secretase expression thus promoting Aβ production [80,81,82,83,84,85]. Studies on human autopsy brain samples from patients with AD and on animal models of AD imply that oxidative damage occurs before Aβ plaque formation [86,87,88]. For example, an increase in reactive nitrogen species coincided with the onset of Aβ deposition in a transgenic AD mouse model [89].

2.3.4. Advanced Glycation End Products (AGEs)
Patients with AD had more AGEs in brain samples than age-matched controls [90]; AGEs were co-localized with NFT and amyloid plaques [91], implying they accelerate aggregation of soluble Aβps and tau into amyloid plaques and NFTs respectively [90,92]. In a cell model, AGEs promoted oxidative stress and inflammation by activation of kappa-light-chain-enhancer of activated B cells (NF-κB) and increased cytokine IL6 gene expression with a concomitant increased release of Aβps [93].

2.3.5. Apolipoprotein E (ApoE) Polymorphism and Cholesterol Levels
ApoE, the principal cholesterol carrier in the brain, is synthetized in astrocytes and transports cholesterol to neurons [94,95]. Persons with two APO-ε4 alleles have the single largest known genetic risk factor for late-onset sporadic AD [10,96,97,98] since APOE-ε4 does not promote the extra- and intra-cellular proteolysis of Aβps as efficiently as the APOE-ε2 or -ε3 isoforms [99]. This is consistent with the finding that MITO dysfunction in AD patients with ApoE-ε4 allele correlates better with cognitive dysfunction, than in AD patients carrying the ApoE-ε3 allele [100]. High serum total cholesterol is an independent risk factor for late onset AD in persons with any combination of ApoE alleles [13]. Supporting experimental evidence is provided by: (a) reduced Aβp production in cultured cells when cholesteryl-ester levels were reduced by inhibiting Acyl-CoA cholesterol acyltransferase (ACAT) [101]; (b) reduced amyloid and tau deposition, by enhancing autophagy with ACAT1 inhibition, in cell culture and whole animal mouse models of AD [102,103,104]; and (c) cholesterol depletion decreased Aβp production in rat hippocampal neurons [105].

2.3.6. Inflammation, Vascular Pathology and Cellular Immunity
Human and animal model studies imply that inflammation promotes Aβ plaque deposition and tau hyperphosphorylation [22,106,107,108,109,110,111,112,113,114,115,116]. For example, post-mortem human AD brains have an increased activation of inflammatory and immune pathways with upregulated levels of pro-inflammatory cytokines, chemokines and complement proteins [108] consistent with microarray studies of brain samples from humans with AD or from animal models of AD that have an increased expression of genes involved in inflammation [109,111]. The intensity of inflammation varies over the course of AD; cytokine activity is the highest in the early clinical course of AD. The reduction of cytokine activity, in the late clinical course of AD, is concomitant with the increased brain levels of Aβ plaque, hyperphosphorylated tau, and AGEs [117]. Animal studies of AD transgenic mice imply that the intra-neuronal Aβ(1-42) is concentrated in neurites and synapses leading to their destruction and leaving a surviving nerve cell with a reduced number of neurites and synapses with adjacent extracellular accumulations of Aβ(1-42) [118]. The magnitude of brain synapse loss in AD correlates well with the degree of cognitive decline [119,120]. This could explain short term memory binding impairment in patients with AD, an early sign of the disease, since the patient’s capacity to form new memories is degraded by loss of synapses [121]. Chronic brain inflammation, as a result of extracellular Aβ(1-42) accumulation following destruction of synapses, neurites and finally neurons, is sustained by an inflammatory response of the surrounding astrocytes and microglia [122,123]. Inflammation increases ROS production that oxidize prostaglandins into F2α-isoprostanes. Both H2O2 and F2α-isoprostanes accelerate aggregation of Aβps into toxic oligomers [49,124]. Extracellular Aβ(1-42): (a) propagates its neurotoxic effects to neighboring nerve cells, an increased extracellular Aβ(1-42) leads to an increased intracellular Aβ(1-42) [18,125,126]; and (b) is further metabolized into less neurotoxic Aβ amyloid plaques by the concomitant inflammatory process [18,127,128,129]. Chronic inflammation, vascular pathology and cellular immune response in the brain are interdependent in AD and tend to re-inforce each other. Aβ(1-42) deposition in brain blood vessel walls accelerates its own brain deposition by promoting vascular damage with subsequent brain hypoperfusion, hypoxia and reduced Aβ(1-42) brain clearance. Thus, the observed vascular defects in AD can be either the cause or consequence of amyloid β accumulation [130]. The role of astroglia and microglia in the evolution of AD is under-investigated, although these cells are vital for normal nerve cell function [130]. Astroglia, a part of the tripartite synapse formed with the pre- and postsynaptic neurons, participates in synapse formation, pruning, maintenance and modulation of synaptic transmission; astroglia cells are also in contact with blood vessels and form, together with neurons, discrete neurovascular clusters [131,132]. Astroglia responds to Aβ(1-42) with an increased, NF-κB mediated, C3 release; C3 binds to neurons and promotes atrophy and elimination of synapses [133]. Astrogliosis, a reaction to brain damage, is present in patients with AD and can be reproduced in animal models of AD. Microglia cells also respond to Aβ(1-42) by promoting inflammation and Aβ(1-42) phagocytosis in the brain [130]. In addition to phagocytosis, microglia also regulate brain nerve cells’ function with synaptic pruning and apoptosis [134]. The role, or different roles over time, of astroglia and microglia on the progression of AD is not well understood; for a recent comprehensive review, see De Strooper and Karran, 2016 [130].

2.3.7. Tau Processing in Alzheimer’s Disease
Tau phosphoprotein promotes tubulin assembly into microtubules and microtubule stability. In the brain, tau is concentrated in neurons and expressed at very low levels in astrocytes and oligodendrocytes [135]. In nerve cells, tau activity is not evenly distributed, but is concentrated at the distal end of axons, presumably to enable optimal stability and plasticity of synapses, the cell-to-cell connections between axon terminals of the upstream nerve and dendrites of the downstream nerve, that propagate the electrochemical stimulation. The breakdown of microtubules is promoted by tau phosphorylation with kinases or caspases; microtubule stability and growth are enhanced by phosphatases, promoting tau dephosphorylation [21,136,137]. Tau hyperphosphorylation leads to the disappearance of microtubules, the breakdown of intracellular traffic, the “dying back” of axons and tau redistribution from an axonal to a somato-dendritic pattern, presumably due to an increased tau synthesis as a response to increased tau hyperphosphorylation [138]. The degree of tau phosphorylation increases with age and is further accelerated by high blood glucose [139,140]. Additional factors that also promote tau hyperphosphorylation are: (a) Aβ(1-42) (via activation of kinases and caspases) [141,142,143]; (b) serine protease inhibitor α1-antichymotrypsin ACT [123]; and (c) oxidative stress [84,144,145,146]. Tau hyperphosphorylation promotes tau self-assembly and NFT formation [147].

2.4. Association of NFTs and Aβ Plaques with the Severity of Cognitive Decline in AD
Post-mortem studies on patients with AD imply a strong association among NFTs, neuronal loss and the severity of cognitive decline [148,149,150]. On the other hand, Aβ plaques seem to appear at the pre-symptomatic stage of AD and their levels stabilize relatively early in the disease process [151].

3. Peptides for Modifying Alzheimer’s Disease
Thus far, the efforts to develop AD therapies, based on “amyloid cascade hypothesis” and NFTs hypotheses, have been disappointing, even when the effective clearing of Aβ deposits in AD brain was demonstrated [152,153,154,155,156,157,158,159,160]. Alternative therapies with antioxidants [161] and anti-inflammatory agents [162,163] were also ineffective. Current drug therapy of AD is symptomatic, to support normal brain synaptic transmission with NMDAR antagonists (to attenuate excessive glutamate release and related nerve cell death rate) and with cholinesterase inhibitors, to conserve acetylcholine synaptic concentration [8,164].

The key issues for development of an efficient AD peptide therapy include: (a) selecting a target for peptide therapy; (b) understanding the relationships among protein sequence, structure, solubility and aggregation [165,166]; (c) integration of chemical kinetics into the drug discovery process to characterize and quantify the inhibition of protein aggregation [167]; (d) development of either Aβ peptide-sequence based or non-Aβ peptide sequence based peptide inhibitors of Aβ aggregation [168]; (e) selection of a drug delivery route [169]; and (f) development of a personalized therapy for AD patients [8,164,168].

3.1. Selecting a Target for Peptide Therapy
3.1.1. Ameliorating AD Cognitive Impairment with Insulin
Brain regions with the highest concentration of insulin receptors are the olfactory bulb, hippocampus and hypothalamus [170,171]. The hippocampus, involved in long-term memory formation, spatial cognition, and conflict processing [172,173,174], has insulin receptors preferentially localized to nerve synapses [175,176]. Research on animal models implies that insulin receptor signaling contributes to long-term memory consolidation and improved spatial learning [171,177,178,179]. Insulin treatment improved memory and cognitive function in patients with AD and in patients with mild cognitive impairment [180,181,182,183,184]. The neuroprotective effects of insulin are mediated by several pathways. (a) Insulin binds to brain receptors and their activation: (i) increases transcription of anti-amyloidogenic proteins insulin-degrading enzyme and α-secretase; and (ii) decreases transcription of pro-amyloidogenic proteins AβPP, β-secretase and glycogen synthase kinase 3 α (Gsk3α) [185,186]. (b) Insulin attenuates Aβ oligomers’ binding to neurons thus protecting synapses against the toxic effects of Aβ oligomers [175]. (c) Insulin increases clearance of brain Aβ(1-42) into the CSF thus reducing Aβ(1-42)’s intracellular accumulation [187]. Insulin improved memory and cognition in patients with AD after a single dose and also after up-to four-months treatment [188,189,190,191,192]. The positive effects of insulin therapy diminish with the progression of AD when increased Aβp levels promote brain insulin resistance [193].

3.1.2. Inhibition of Aβ Peptide Synthesis and Therapies with Tau Inhibitors, Aβ Peptide Chelators or Antibodies
Inhibitors were designed and tested that block APP expression or prevent proteolytic cleavage of APP into Aβps. Inhibition of γ-secretase, an enzyme involved in many physiological reactions, also lead to impaired lymphocyte differentiation and altered intestinal development [194,195]. β-secretase inhibitors are large molecules that are prevented by the blood–brain barrier (BBB) to reach their target [196,197]. Thus far, all inhibitors of β- or γ-secretase failed during clinical trials [198,199,200,201,202,203,204,205,206]. Chelation therapies, to disrupt interactions between Aβps and metal, were also not successful [207,208,209,210]. The only tau inhibitor molecule under clinical trials is phenothiazine methylene blue [211,212,213,214]. Antibody therapies for AD failed due to the antibodies’ inability to cross the BBB [215,216,217,218].

3.1.3. Inhibition of Aβ Peptide Aggregation and Amyloid Formation
In principle, small molecules that inhibit Aβ aggregation [219,220,221,222,223,224] should not disrupt the normal biochemical processes in the body. However, their design is challenging for several reasons: (a) in contrast to protein-protein interactions that occur over large surface areas [225,226], protein-small molecule interactions occur over 3–5 times smaller contact surfaces [227,228]; and (b) regions of protein-protein interactions are relatively featureless and variable [229,230,231]. The discovery of key regions in the Aβ peptide sequence (i.e., N-terminus, hydrophobic core, hinge/turn region and C-terminus), responsible for Aβ plaque formation, was essential for the rational development of peptide inhibitors of amyloidogenesis [232,233,234,235,236,237,238].

Aβ peptides undergo several conformational changes: from an α-helix (i.e., random coil) native structure ⇒ to an intermediate α-sheet ⇒ to a β-sheet (i.e., highly ordered, with exposed hydrophobic amino acid residues that promote Aβp aggregation) structure present in amyloid fibrils, the building blocks of Aβ plaques. The intermediate α-sheet configuration has the propensity to aggregate into colloidal spheres that spontaneously form linear chains, the first step in amyloid fibril formation [239]. The conversion from the intermediate α-sheet to the β-sheet conformation has been inferred from protein crystal structure analysis [240,241,242] and studies with inhibitors of Aβ peptide aggregation [243]. Aβp intermediates and oligomers, that chronologically precede amyloid fibril formation, have heterogeneous conformations [244,245,246] that also change with age [247]. The Aβ plaques also contain a diverse population of truncated or modified Aβ peptides [248]. The Aβ peptide’s α-helix native structure can be stabilized or its β-sheet structure destabilized which has important implications for development of AD modifying therapies [196,249,250,251].

1. Aβp Sequence Derived Peptides

This group of peptides is based on the central hydrophobic core (CHC) sequence Aβ(16-20/22) and includes peptides with natural or modified amino-acids. The natural amino-acid peptides inhibit Aβ aggregation, but have the disadvantages of self-association into fibrils and low proteolytic stability. These disadvantages were ameliorated by various modifications including N-methylation [252], d-amino acid incorporation, retro-inverso peptides, replacement of amide by ester bonds, and cyclization [168].

• Natural Aβp sequence derived peptides

An example of a natural Aβ sequence derived peptide is the oligopeptide Ac-Leu-Pro-Phe-Phe-Asp-NH2 (iAb5p), where a proline and an aspartic acid amide substitute the valine and the alanine, respectively. This peptide crosses the BBB; in vivo, it inhibits formation of amyloid fibrils and promotes disassembly of formed amyloid plaques. The efficacy of this synthetic peptide is contributed to its proline residues that attenuate the β-sheet confirmation propensity of the natural Aβ peptides [249].

• Modified Aβp sequence derived peptides

Fluorinated Aβ sequence derived peptides are produced by fluorination of hydrophobic amino acids valine or phenylalanine. Fluorinated amino acids bind with hydrophobic residues of Aβps, thus preventing contact between Aβ peptide molecules and inhibiting their aggregation [253,254].

d-peptides are more resistant to proteolytic enzymes than their l-isomers. d-peptides inhibited Aβ aggregation in an animal model [255].

Retro-Inverso modified Aβ sequence derived peptides are derived from peptides by substituting the l-amino acids for their d-counterparts and reversing the sequence to mimic the original peptide since they retain the same spatial positioning of the side chains and 3D structure [244,256,257]. These peptides combine the advantage of the original peptide (i.e., inhibition of aggregation) with an increased resistance to enzymatic proteolysis, a reduced self-aggregation and an improved ability to cross the BBB in an animal model [258,259,260,261,262].

Cyclic peptides were developed from KLVFF derivatives. They are strong and specific inhibitors of amyloid formation. Compared to their noncyclic equivalents, they are metabolized more slowly due to their resistance to enzymatic degradation [244,263,264].

N-methylated peptides (e.g., SEN304 and SEN1576) inhibit Aβp mediated toxicity in an animal model. They do not inhibit Aβp aggregation, they divert Aβp aggregation into non-toxic forms and remove toxic oligomers [265,266].

α sheet peptides have alternating d-amino acids and l-amino acids; they reduce Aβ aggregation and toxicity but lack the ability to cross the BBB [267].

2. Peptides not derived from Aβp sequence

Peptides not derived from Aβp sequence and peptides derived from Aβ sequence share the qualities of hydrophobicity and the ability to incorporate into the β-sheets structure, thus inhibiting Aβp aggregation.

• Peptides not derived from Aβp sequence containing natural amino acids

Examples are NAP [268], carnosine [269,270] and hexapeptides [271]. All of them inhibit Aβ peptide aggregation. NAP also attenuated mild cognitive impairment in phase II clinical trials [272,273].

• Peptides not derived from Aβp sequence containing modified amino acids

D-4F improved cognitive function when administered orally to mice and also inhibited Aβp deposition [274].

Cyclic peptide PP-Leu is a tridecapeptide analogue of theta-defensins. This peptide combines the ability to inhibit Aβ oligomer and amyloid fibril formation, by sequestration of amyloidogenic Aβ peptides into colloid-like assemblies, with a high resistance to endoproteinase K [275].

3.2. Relationship between Protein Sequence, Structure, Solubility and Aggregation
Protein aggregation is regulated by the same physicochemical laws as normal protein folding and shares many common features with other thermodynamically stable protein conformations [276]. Protein solubility is an essential feature for successful development of AD peptide therapy; proteins in aggregates lose their therapeutic effect, can become toxic or increase the probability for an immune response in the treated patient [277,278].

Protein aggregation prediction methods are based on the analysis of physicochemical factors that determine protein thermodynamics and kinetics of unfolded polypeptide aggregation [279,280], the discovery of key regions in the Aβ peptide sequence responsible for Aβ plaque formation [281,282,283,284,285,286,287,288] and advances in modelling and simulation of aggregation-prone regions, recently reviewed by Trainor et al. [166]. The discovery of aggregation-prone regions in Aβ peptides is essential for the rational development of peptides that reduce the Aβ peptides’ tendency to form ordered intermolecular assemblies [289,290,291]. The regions of Aβ(1-42) and Aβ(1-40), with a high aggregation propensity, are the central region (residues 18–22) and the C-terminal region (residues 32–42) [236,292,293]. In solution, Aβ peptides are largely unstructured with no stable folded structure [165].

Aggregation prediction algorithms were classified by Trainor et al. into amino acid composition-based algorithms, sliding window/pattern-based algorithms and tertiary/quaternary structure-based algorithms [166].

3.2.1. Amino Acid Composition-Based Algorithms
Amino acid composition-based algorithms use statistical analyses and machine learning algorithms to predict/generalize aggregation-prone regions based on amino acid sequences of proteins with known aggregation propensities. These algorithms use amino acid and/or dipeptide frequencies to determine peptide solubility in a binary manner (either soluble or insoluble) and disregard the position of each amino acid in the studied peptide sequence. Therefore, they cannot pinpoint specific amino acid changes with the greatest aggregation impact [3,166,279,294,295,296,297,298,299]. To improve solubility predictions of amino acid composition-based algorithms, parameters are included that reflect the order of the amino acids in the studied protein sequence, for example Shannon entropy and parameters derived from Chaos Game Representations of amino acid sequences [296,300]. To summarize, these methods are more appropriate for binary, proteome wide, solubility surveys and less for optimizing protein solubility of AD modifying peptides [166].

3.2.2. Sliding Window/Pattern-Based Algorithms
The sliding window methods can analyze amino acid sequences for aggregation-prone regions that can be as short as five amino acid residues. They are based on the theoretically and experimentally verified premise that 5–7 residue sequence segments can exert a disproportionate influence on protein solubility. Protein solubility is estimated by considering the contributions of charge, hydrophobicity/hydrophilicity ratio, secondary structure propensity, statistical analysis of residue pairings between adjacent β-strands in known structures and patterns of residue distribution in amyloidogenic hexapeptides [165,282,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317]. CamSOL incorporates the sliding window method to develop soluble antibodies targeting Aβ peptides [313]. Other examples of tools using the sliding window method to study Aβ peptides aggregation are AmyloidMutants [310], STITCHER [318], AGGRESCAN [301,316] and Ziggregator [165]. The sliding window based methods can recognize amino acid sequence features relevant to aggregation of Aβ peptides. However, the composition of Aβ peptide aggregates varies, is not homogenous [287]. In addition, most sliding window method based tools do not include information on protein structure that influences exposure of aggregation prone regions; a limited exposure of aggregation prone regions can change the agreement between aggregation propensity predictions and experimentally measured aggregation [166]. None of the sliding window methods explicitly take into account the tertiary/quaternary structure of a native protein although associations between natively folded proteins can indirectly impact aggregation kinetics of partially or fully unfolded proteins [277]; in addition, aggregates may be formed by partially unfolded/structured proteins [319,320,321].

3.2.3. Tertiary/Quaternary Structure-Based Algorithms
Structure based methods [313,322,323,324,325] reliably predict protein aggregation even when a significant number of aggregation-prone regions is inaccessible; for example when transient (α-sheet) or stable (β-sheet) associations between folded Aβ proteins accelerate aggregation [166]. Examples of structure based methods are SAP [326], the upgraded version of CamSol [165] and AGGRESCAN3D [166]. The SAP method can grade cytotoxicity of Aβ(1-42) peptide variants [326].

3.3. Integration of Chemical Kinetics into the Drug Discovery Process to Charaterize and Quantify the Inhibition of Protein Aggregation
3.3.1. Challenges in Understanding Aggregation Inhibition Mechanisms at the Molecular Level
The key step in Aβ plaque formation are conformational changes of Aβ peptides into reactive, metastable oligomers (i.e., the primary nucleation processes) that assemble into protofibrils and later fibrils [327]. Aggregation of Aβ peptides is further accelerated by the secondary nucleation processes triggered by fibril fragmentation and fibril surface catalyzed nucleation [328,329]. The kinetics of fibril formation follow a sigmoidal curve, preceded by a lag phase and terminated by a plateau after Aβ monomer depletion [330,331]. Most inhibitors attenuate Aβ peptide aggregation by forming covalent or noncovalent bonds with one or more products of the aggregation pathway. For example, aromatic compounds sequester protein monomers and/or oligomers in a nonspecific manner [332,333]. A variety of methods is necessary to quantify the binding characteristics of Aβ peptides’ monomers and oligomers with peptide inhibitors [50,333,334,335,336,337,338,339].

3.3.2. Kinetic Analysis of Aggregation Inhibition Mechanisms Is Necessary for Development and Evaluation of Drug-Like Small Molecules
Arosio et al. present a strategy that integrates experimental characterization of Aβ peptide products with chemical kinetics (i.e., reaction kinetics) to facilitate a rational design and evaluation of peptides for AD therapy [167]. The advantage of chemical kinetics is the method’s ability to measure very weak binding events and their effects, an important characteristic of inhibitor–protein interactions. This method evaluates how different experimental conditions influence the speed of reactions that generate Aβ oligomers, protofibrils and fibrils, yielding information about the reactions’ mechanisms and transition states [340,341]. Chemical kinetics can model the effect of: (a) protein structural changes due to binding [342]; (b) covalent reactions between proteins and inhibitors [343]; (c) off-pathways (i.e., non-amyloidogenic pathways) that also produce toxic soluble oligomers [50]; and (d) Aβ aggregation inhibitors that reduce the amount of toxic Aβ oligomers by redirecting the aggregation process to alternative off-pathway products [334,339,343,344,345].

Kinetic analysis of Aβ peptide aggregation inhibition mechanisms evaluates how the inhibitions of primary nucleation, secondary nucleation or elongation individually contribute to Aβ fibril formation. For example: (a) inhibition of monomer formation decreases the rate of primary and secondary nucleation and fibril elongation; (b) inhibition of oligomer production reduces primary and secondary nucleation rates; (c) inhibitor binding to the fibril ends slows down the fibril elongation process; and (d) inhibitor binding to amyloid fibrils decreases only the surface catalyzed secondary nucleation rate [167]. In addition, kinetic analysis can: (a) distinguish between the effects of fibril elongation and secondary nucleation on lag-time phases and growth rates of fibril mass fraction; (b) quantify the effect of primary nucleation inhibition on the lag-time preceding the fibril mass growth phase; (c) demonstrate that the final quantity of fibril mass fraction is reduced only by the inhibition of primary nucleation and fibril elongation processes; and (d) demonstrate that the inhibition of primary nucleation and fibril elongation processes delay formation of the toxic Aβ oligomer intermediates, but only the inhibition of secondary nucleation attenuates the maximum amount of toxic Aβ oligomers [167].

In summary, the chemical kinetics data can be used to build mathematical models of Aβp forming reactions to: (a) better understand and describe chemical processes governing peptide inhibitor-Aβ peptide products interactions; and (b) to design or modify peptide inhibitors of Aβ peptide aggregation [330,331,337,346,347,348].

3.4. Selection of Drug Delivery Route
Efficient brain delivery over the BBB is essential for peptide based AD treatment [169]. Intravenous peptide administration, in an animal model, leads to a brain peptide content of less <1% of the administered dose [349]. Therefore, intraperitoneal injection or intracerebral infusion are the preferred drug delivery routes to study the effect of anti-AD peptides in animal models [350,351,352,353,354]. For example, intraperitoneal injection of TFP5, an inhibitor Cdk5/p25 activity, attenuated tau hyperphosphorylation, neurofilament formation, Aβp accumulation and inflammation in mice brains [355]. In human, intraperitoneal injection or intracerebral infusion are not practical administration routes for long term treatment. An alternative to both, oral administration, was tested in animals with the anti-AD peptide D3; however, the peptide only elicited an improvement in cognitive behavior and a reduction in amyloid deposition with the use of very large doses (0.5–1 mg/mouse/day) [356]. Experiments with radioactively labeled exendin (9–39) imply that intranasal delivery is the only non-invasive drug delivery route, studied in an animal model, that could be used as a testing model for long term treatment in human; it has also a considerably higher peptide delivery to the brain than intravenous administration [357]. The use of polyethylenimine (PEI) conjugated peptides (e.g., V24P(10-40)-PEI), or peptides with a cell-penetrating peptide segment with multiple positively charged residues (e.g., wtNBD), further increase peptide brain delivery efficiency, to more than 17% of the intranasally administered dose [358,359].

Intranasal application of potential anti-AD peptides for human treatment (e.g., wtNBD, PACAP38 and NAP) reduced amyloidopathy in animal models by targeting diverse amyloidogenic pathways. For example: (a) wtNBD inhibits the induction of NF-κB activation, suppresses microglial activation, attenuates Aβ plaque deposition and improves cognition [358]; (b) PACAP38 increases α-secretase activity and improves cognition [360]; and (c) NAP promotes microtubule assembly, attenuates Aβ peptide accumulation and tau hyperphosphorylation [273,361]. The efficiency of intranasally delivered antiamyloidogenic peptides could be further enhanced by increasing their protease resistance [169]. The strategy to treat AD in human, with intranasal application of peptides, is also vindicated by phase 2 clinical trials on AD patients with intranasal insulin application that improved cognition [181,183,189,191,362,363,364,365].

3.5. Summary of Presented AD Modifying Peptides
A summary of AD modifying peptides, including references, is presented in Table 1.

3.6. Development of a Personalized Therapy for AD Patients
Several research groups have recently articulated the need for a personalized approach to the treatment of patients with AD, a multifactorial disease due to a combination of genes and environmental factors [8,164,169]. Peng et al. proposed a stage-specific strategy for a comprehensive and personalized treatment of patients with AD. This strategy includes genome editing of AD associated mutations, physical activity, brain stimulation, adequate social communication, appropriate diet, multiple drug therapy targeting amyloidogenesis and inflammation or stimulating brain blood flow and neuronal regeneration with stem cell technology [164].

4. Conclusions
AD is a progressive neurodegenerative disorder, where the rate of disease progression varies considerably from person to person due to life style, genetic and environmental factors. Chronic inflammation, vascular pathology and accumulation of toxic Aβ peptide products tend to sustain and re-inforce each other overtime, and these processes are accompanied by changes in brain structure, connectivity and function. Therefore, an effective peptide based AD therapy has to be personalized and stage specific. Chemical kinetics and aggregation prediction algorithms are essential tools for the development of peptide based AD modifying drugs, and intranasal application is the preferred delivery route for the development and treatment with anti-amyloidogenic peptides.

Acknowledgments
This work was supported by ARRS grant number P3-0171.

Conflicts of Interest
The author declares no conflicts of interest.

Figure 1 Pathways of amyloid precursor protein proteolysis, amyloid plaque formation and targets of selected peptide inhibitors. Abbreviations: 83-CTF (83-amino acid membrane bound C-terminal fragment); 99-CTF (99-amino acid membrane bound C-terminal fragment); AP (amyloid plaque); APP (amyloid precursor protein); APP-ICD (APP intracellular domain); Aβ′ (misfolded Aβ peptide with first α-sheet, then β-sheet structure); Aβn (native Aβ peptide with α-helix structure); AβD (amyloid β dimer); AβFs (amyloid β fibrils); AβM (amyloid β monomer); AβO (amyloid β oligomer); AβPF (amyloid β protofibril); IDE (insulin degrading enzyme); NFT (neurofibrillary tangles); nonT-AβD (non-toxic amyloid β dimer); nonT-AβO (non-toxic amyloid β oligomer); NS (nucleation site); NSAIDs (nonsteroidal anti-inflammatory drugs); PI (peptide inhibitor with examples in parentheses); SAPPα (soluble peptide APPα); SAPPβ (soluble peptide APPβ); ⊥ attenuates/inhibits, α-S (α-secretase); β-S (β-secretase); γ-S (γ-secretase); ⊕ promotes/accelerates.

molecules-23-00283-t001_Table 1Table 1 AD modifying peptides with brief description. Abbreviations: act. (activity); agg. (aggregation); att. (attenuates); hyperph. (hyperphosphorylation); infl. (inflammation); NFF (neurofilament formation); pII. c.t. (phase II clinical trials); pl. form. (plaque formation); ref. (reference); stim. (stimulates); α-S (α-secretase); ● (observed effect).

Peptide Name and Ref.	Att. Brain Infl.	Att. Aβp Agg./Pl. Form.	Att. Tau Hyperph./NFF	Stim. Neurog.	Improves Cognition	Stim. α-S Act.	
Ac-Leu-Pro-Phe-Phe-Asp-NH2 (iAb5p), [249]	
	●	
	
	
	
	
LPfFFD-PEG, [253,254]	
	●	
	
	
	
	
D-(PGKLVYA), [255]	
	●	
	
	
	
	
RI-OR2-TAT, [260]	●	●	
	●	
	
	
cyclo(17, 21)-(Lys17, Asp21)Aβ(1-28), [366]	
	●	
	
	
	
	
SEN304, SEN1576, [265,266]	
	●	
	
	
	
	
α sheet peptides, [267]	
	●	
	
	
	
	
NAP, [268,273,361]	
	●	●	
	● (pII. c.t.)	
	
D4-F, [274]	
	●	
	
	●	
	
D3, [356]	
	●	
	
	●	
	
PP-Leu, [275]	
	●	
	
	
	
	
TFP5, [355]	●	●	●	
	
	
	
wtNBD, [358]	●	●	
	
	●	
	
PACAP38, [360]	
	
	
	
	●	●	
insulin, [181,183,189,191,362,363,364,365]	
	
	
	
	● (pII. c.t.)
==== Refs
References
1. Querfurth H.W.  LaFerla F.M.   Alzheimer’s disease N. Engl. J. Med. 2010 362 329 344 10.1056/NEJMra0909142 20107219 
2. Pahnke J.  Walker L.C.  Scheffler K.  Krohn M.   Alzheimer’s disease and blood-brain barrier function—Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci. Biobehav. Rev. 2009 33 1099 1108 10.1016/j.neubiorev.2009.05.006 19481107 
3. Prince M.  Comas-Herrera A.  Knapp M.  Guerchet M.  Karagiannidou M.   World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia: Coverage, Quality and Costs Now and in the Future Alzheimer’s Disease International (ADI) London, UK 2016 
4. Freiherr J.  Hallschmid M.  Frey W.H.  Brünner Y.F.  Chapman C.D.  Hölscher C.  Craft S.  De Felice F.G.  Benedict C.   Intranasal insulin as a treatment for Alzheimer’s disease: A review of basic research and clinical evidence CNS Drugs 2013 27 505 514 10.1007/s40263-013-0076-8 23719722 
5. Correia S.C.  Santos R.X.  Carvalho C.  Cardoso S.  Candeias E.  Santos M.S.  Oliveira C.R.  Moreira P.I.   Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer’s disease and diabetes interrelation Brain Res. 2012 1441 64 78 10.1016/j.brainres.2011.12.063 22290178 
6. Vandal M.  Bourassa P.  Calon F.   Can insulin signaling pathways be targeted to transport abeta out of the brain? Front. Aging Neurosci. 2015 7 114 10.3389/fnagi.2015.00114 26136681 
7. Yang Y.  Song W.   Molecular links between Alzheimer’s disease and diabetes mellitus Neuroscience 2013 250 140 150 10.1016/j.neuroscience.2013.07.009 23867771 
8. Chen Z.  Zhong C.   Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies Prog. Neurobiol. 2013 108 21 43 10.1016/j.pneurobio.2013.06.004 23850509 
9. Jeong S.   Molecular and cellular basis of neurodegeneration in Alzheimer’s disease Mol. Cells 2017 40 613 620 10.14348/molcells.2017.0096 28927263 
10. Corder E.  Saunders A.  Strittmatter W.  Schmechel D.  Gaskell P.  Small G.  Roses A.  Haines J.  Pericak-Vance M.   Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer’s disease in late onset families Science 1993 261 921 923 10.1126/science.8346443 8346443 
11. Hoyer S.   Causes and consequences of disturbances of cerebral glucose metabolism in sporadic alzheimer disease: Therapeutic implications Front. Clin. Neurosci. 2004 135 152 10.1007/978-1-4419-8969-7_8 
12. Irie F.  Fitzpatrick A.L.  Lopez O.L.  Kuller L.H.  Peila R.  Newman A.B.  Launer L.J.   Enhanced risk for alzheimer disease in persons with type 2 diabetes and apoe epsilon4: The cardiovascular health study cognition study Arch. Neurol. 2008 65 89 93 10.1001/archneurol.2007.29 18195144 
13. Kivipelto M.   Apolipoprotein e ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life alzheimer disease Ann. Intern. Med. 2002 137 149 10.7326/0003-4819-137-3-200208060-00006 12160362 
14. Luchsinger J.A.  Reitz C.  Patel B.  Tang M.-X.  Manly J.J.  Mayeux R.   Relation of diabetes to mild cognitive impairment Arch. Neurol. 2007 64 570 575 10.1001/archneur.64.4.570 17420320 
15. Ott A.  Stolk R.P.  van Harskamp F.  Pols H.A.P.  Hofman A.  Breteler M.M.B.   Diabetes mellitus and the risk of dementia: The rotterdam study Neurology 1999 53 1937 10.1212/WNL.53.9.1937 10599761 
16. Rocchi A.  Pellegrini S.  Siciliano G.  Murri L.   Causative and susceptibility genes for Alzheimer’s disease: A review Brain Res. Bull. 2003 61 1 24 10.1016/S0361-9230(03)00067-4 12788204 
17. Tarasoff-Conway J.M.  Carare R.O.  Osorio R.S.  Glodzik L.  Butler T.  Fieremans E.  Axel L.  Rusinek H.  Nicholson C.  Zlokovic B.V.    Clearance systems in the brain-implications for alzheimer disease Nat. Rev. Neurol. 2015 11 457 470 10.1038/nrneurol.2015.119 26195256 
18. Gouras G.K.  Tampellini D.  Takahashi R.H.  Capetillo-Zarate E.   Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease Acta Neuropathol. 2010 119 523 541 10.1007/s00401-010-0679-9 20354705 
19. Kolb B.  Whishaw I.Q.   Plasticity in the neocortex: Mechanisms underlying recovery from early brain damage Prog. Neurobiol. 1989 32 235 276 10.1016/0301-0082(89)90023-3 2655008 
20. Li N.  Daie K.  Svoboda K.  Druckmann S.   Robust neuronal dynamics in premotor cortex during motor planning Nature 2016 532 459 464 10.1038/nature17643 27074502 
21. O’Brien R.J.  Wong P.C.   Amyloid precursor protein processing and Alzheimer’s disease Annu. Rev. Neurosci. 2011 34 185 204 10.1146/annurev-neuro-061010-113613 21456963 
22. Lee J.  Retamal C.  Cuitiño L.  Caruano-Yzermans A.  Shin J.-E.  van Kerkhof P.  Marzolo M.-P.  Bu G.   Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes J. Biol. Chem. 2008 283 11501 11508 10.1074/jbc.M800642200 18276590 
23. Koo E.H.  Squazzo S.L.   Evidence that production and release of amyloid beta-protein involves the endocytic pathway J. Biol. Chem. 1994 269 17386 17389 8021238 
24. Kinoshita A.   Demonstration by fret of bace interaction with the amyloid precursor protein at the cell surface and in early endosomes J. Cell Sci. 2003 116 3339 3346 10.1242/jcs.00643 12829747 
25. Tanzi R.E.  Bertram L.   Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective Cell 2005 120 545 555 10.1016/j.cell.2005.02.008 15734686 
26. Giuffrida M.L.  Caraci F.  Pignataro B.  Cataldo S.  De Bona P.  Bruno V.  Molinaro G.  Pappalardo G.  Messina A.  Palmigiano A.    Beta-amyloid monomers are neuroprotective J. Neurosci. 2009 29 10582 10587 10.1523/JNEUROSCI.1736-09.2009 19710311 
27. Fukumori A.  Okochi M.  Tagami S.  Jiang J.  Itoh N.  Nakayama T.  Yanagida K.  Ishizuka-Katsura Y.  Morihara T.  Kamino K.    Presenilin-dependent gamma-secretase on plasma membrane and endosomes is functionally distinct† Biochemistry 2006 45 4907 4914 10.1021/bi052412w 16605258 
28. Parvathy S.  Hussain I.  Karran E.H.  Turner A.J.  Hooper N.M.   Cleavage of alzheimer’s amyloid Precursor protein by α-secretase occurs at the surface of neuronal cells Biochemistry 1999 38 9728 9734 10.1021/bi9906827 10423252 
29. Barger S.W.  Harmon A.D.   Microglial activation by alzheimer amyloid precursor protein and modulation by apolipoprotein E Nature 1997 388 878 881 10.1038/42257 9278049 
30. Meziane H.  Dodart J.C.  Mathis C.  Little S.  Clemens J.  Paul S.M.  Ungerer A.   Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice Proc. Natl. Acad. Sci. USA 1998 95 12683 12688 10.1073/pnas.95.21.12683 9770546 
31. Caporaso G.L.  Gandy S.E.  Buxbaum J.D.  Ramabhadran T.V.  Greengard P.   Protein phosphorylation regulates secretion of alzheimer beta/a4 amyloid precursor protein Proc. Natl. Acad. Sci. USA 1992 89 3055 3059 10.1073/pnas.89.7.3055 1557413 
32. Lannfelt L.  Basun H.  Wahlund L.-O.  Rowe B.A.  Wagner S.L.   Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for alzheimer’s diseas Nat. Med. 1995 1 829 832 10.1038/nm0895-829 7585189 
33. Savage M.J.  Trusko S.P.  Howland D.S.  Pinsker L.R.  Mistretta S.  Reaume A.G.  Greenberg B.D.  Siman R.  Scott R.W.   Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester J. Neurosci. 1998 18 1743 1752 9464999 
34. Van Nostrand W.E.  Wagner S.L.  Shankle W.R.  Farrow J.S.  Dick M.  Rozemuller J.M.  Kuiper M.A.  Wolters E.C.  Zimmerman J.  Cotman C.W.   Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live alzheimer disease patients Proc. Natl. Acad. Sci. USA 1992 89 2551 2555 10.1073/pnas.89.7.2551 1557359 
35. Ehehalt R.  Keller P.  Haass C.  Thiele C.  Simons K.   Amyloidogenic processing of the alzheimer beta-amyloid precursor protein depends on lipid rafts J. Cell Biol. 2003 160 113 123 10.1083/jcb.200207113 12515826 
36. Parkin E.T.  Hussain I.  Karran E.H.  Turner A.J.  Hooper N.M.   Characterization of detergent-insoluble complexes containing the familial Alzheimer’s disease-associated presenilins J. Neurochem. 2001 72 1534 1543 10.1046/j.1471-4159.1999.721534.x 
37. Parkin E.T.  Turner A.J.  Hooper N.M.   Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein Biochem. J. 1999 344 23 30 10.1042/bj3440023 10548529 
38. Riddell D.R.  Christie G.  Hussain I.  Dingwall C.   Compartmentalization of beta-secretase (asp2) into low-buoyant density, noncaveolar lipid rafts Curr. Biol. 2001 11 1288 1293 10.1016/S0960-9822(01)00394-3 11525745 
39. Wahrle S.  Das P.  Nyborg A.C.  McLendon C.  Shoji M.  Kawarabayashi T.  Younkin L.H.  Younkin S.G.  Golde T.E.   Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains Neurobiol. Dis. 2002 9 11 23 10.1006/nbdi.2001.0470 11848681 
40. Hooper N.M.   Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein Biochem. Soc. Trans. 2005 33 335 338 10.1042/BST0330335 15787600 
41. Hardy J.   The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics Science 2002 297 353 356 10.1126/science.1072994 12130773 
42. Fassbender K.  Simons M.  Bergmann C.  Stroick M.  Lutjohann D.  Keller P.  Runz H.  Kuhl S.  Bertsch T.  von Bergmann K.    Simvastatin strongly reduces levels of Alzheimer’s disease beta -amyloid peptides abeta 42 and abeta 40 in vitro and in vivo Proc. Natl. Acad. Sci. USA 2001 98 5856 5861 10.1073/pnas.081620098 11296263 
43. Kojro E.  Gimpl G.  Lammich S.  Marz W.  Fahrenholz F.   Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase adam 10 Proc. Natl. Acad. Sci. USA 2001 98 5815 5820 10.1073/pnas.081612998 11309494 
44. Abramov E.  Dolev I.  Fogel H.  Ciccotosto G.D.  Ruff E.  Slutsky I.   Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses Nat. Neurosci. 2009 12 1567 1576 10.1038/nn.2433 19935655 
45. LaFerla F.M.  Green K.N.  Oddo S.   Intracellular amyloid-beta in Alzheimer’s disease Nat. Rev. Neurosci. 2007 8 499 509 10.1038/nrn2168 17551515 
46. Ma L.  Ohyagi Y.  Miyoshi K.  Sakae N.  Motomura K.  Taniwaki T.  Furuya H.  Takeda K.  Tabira T.  Kira J.   Increase in p53 protein levels by presenilin 1 gene mutations and its inhibition by secretase inhibitors J. Alzheimer Dis. 2009 16 565 575 10.3233/JAD-2009-0990 19276551 
47. Ohyagi Y.   Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer’s disease Curr. Alzheimer Res. 2008 5 555 561 10.2174/156720508786898514 19075582 
48. Ohyagi Y.  Asahara H.  Chui D.H.  Tsuruta Y.  Sakae N.  Miyoshi K.  Yamada T.  Kikuchi H.  Taniwaki T.  Murai H.    Intracellular abeta42 activates p53 promoter: A pathway to neurodegeneration in Alzheimer’s disease FASEB J. 2005 19 255 257 10.1096/fj.04-2637fje 15548589 
49. Gandy S.   The role of cerebral amyloid beta accumulation in common forms of alzheimer disease J. Clin. Investig. 2005 115 1121 1129 10.1172/JCI25100 15864339 
50. Necula M.  Kayed R.  Milton S.  Glabe C.G.   Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct J. Biol. Chem. 2007 282 10311 10324 10.1074/jbc.M608207200 17284452 
51. Funk K.E.  Kuret J.   Lysosomal fusion dysfunction as a unifying hypothesis for Alzheimer’s disease pathology Int. J. Alzheimers Dis. 2012 10.1155/2012/752894 22970406 
52. Khosravani H.  Zhang Y.  Tsutsui S.  Hameed S.  Altier C.  Hamid J.  Chen L.  Villemaire M.  Ali Z.  Jirik F.R.    Prion protein attenuates excitotoxicity by inhibiting nmda receptors J. Cell Biol. 2008 181 551 565 10.1083/jcb.200711002 18443219 
53. Stys P.K.  You H.  Zamponi G.W.   Copper-dependent regulation of nmda receptors by cellular prion protein: Implications for neurodegenerative disorders J. Physiol. 2012 590 1357 1368 10.1113/jphysiol.2011.225276 22310309 
54. Gu Z.  Liu W.  Yan Z.   β-amyloid impairs ampa receptor trafficking and function by reducing Ca2+ /calmodulin-dependent protein kinase ii synaptic distribution J. Biol. Chem. 2009 284 10639 10649 10.1074/jbc.M806508200 19240035 
55. Tyszkiewicz J.P.   β-amyloid peptides impair pkc-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons J. Neurophysiol. 2005 93 3102 3111 10.1152/jn.00939.2004 15659527 
56. Hamilton A.  Zamponi G.W.  Ferguson S.S.G.   Glutamate receptors function as scaffolds for the regulation of beta-amyloid and cellular prion protein signaling complexes Mol. Brain 2015 8 10.1186/s13041-015-0107-0 25888324 
57. Lue L.-F.  Kuo Y.-M.  Roher A.E.  Brachova L.  Shen Y.  Sue L.  Beach T.  Kurth J.H.  Rydel R.E.  Rogers J.   Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease Am. J. Pathol. 1999 155 853 862 10.1016/S0002-9440(10)65184-X 10487842 
58. McLean C.A.  Cherny R.A.  Fraser F.W.  Fuller S.J.  Smith M.J.  Beyreuther K.  Bush A.I.  Masters C.L.   Soluble pool of abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease Ann. Neurol. 1999 46 860 866 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M 10589538 
59. Lambert M.P.  Barlow A.K.  Chromy B.A.  Edwards C.  Freed R.  Liosatos M.  Morgan T.E.  Rozovsky I.  Trommer B.  Viola K.L.    Diffusible, nonfibrillar ligands derived from Aβ1–42  are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. USA 1998 95 6448 6453 10.1073/pnas.95.11.6448 9600986 
60. Shankar G.M.  Li S.  Mehta T.H.  Garcia-Munoz A.  Shepardson N.E.  Smith I.  Brett F.M.  Farrell M.A.  Rowan M.J.  Lemere C.A.    Amyloid-beta protein dimers isolated directly from alzheimer’s brains impair synaptic plasticity and memory Nat. Med. 2008 14 837 842 10.1038/nm1782 18568035 
61. Townsend M.  Shankar G.M.  Mehta T.  Walsh D.M.  Selkoe D.J.   Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: A potent role for trimers J. Physiol. 2006 572 477 492 10.1113/jphysiol.2005.103754 16469784 
62. Wang H.-W.  Pasternak J.F.  Kuo H.  Ristic H.  Lambert M.P.  Chromy B.  Viola K.L.  Klein W.L.  Stine W.B.  Krafft G.A.    Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus Brain Res. 2002 924 133 140 10.1016/S0006-8993(01)03058-X 11750898 
63. Cleary J.P.  Walsh D.M.  Hofmeister J.J.  Shankar G.M.  Kuskowski M.A.  Selkoe D.J.  Ashe K.H.   Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function Nat. Neurosci. 2004 8 79 84 10.1038/nn1372 15608634 
64. Lesné S.  Koh M.T.  Kotilinek L.  Kayed R.  Glabe C.G.  Yang A.  Gallagher M.  Ashe K.H.   A specific amyloid-beta protein assembly in the brain impairs memory Nature 2006 440 352 357 10.1038/nature04533 16541076 
65. Poling A.  Morgan-Paisley K.  Panos J.J.  Kim E.-M.  O’Hare E.  Cleary J.P.  Lesné S.  Ashe K.H.  Porritt M.  Baker L.E.   Oligomers of the amyloid-beta protein disrupt working memory: Confirmation with two behavioral procedures Behav. Brain Res. 2008 193 230 234 10.1016/j.bbr.2008.06.001 18585407 
66. Shankar G.M.  Bloodgood B.L.  Townsend M.  Walsh D.M.  Selkoe D.J.  Sabatini B.L.   Natural oligomers of the alzheimer amyloid-beta protein induce reversible synapse loss by modulating an nmda-type glutamate receptor-dependent signaling pathway J. Neurosci. 2007 27 2866 2875 10.1523/JNEUROSCI.4970-06.2007 17360908 
67. Butterfield D.A.  Galvan V.  Lange M.B.  Tang H.  Sowell R.A.  Spilman P.  Fombonne J.  Gorostiza O.  Zhang J.  Sultana R.    In vivo oxidative stress in brain of alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of app Free Radic. Biol. Med. 2010 48 136 144 10.1016/j.freeradbiomed.2009.10.035 19854267 
68. Al-Hilaly Y.K.  Williams T.L.  Stewart-Parker M.  Ford L.  Skaria E.  Cole M.  Bucher W.  Morris K.L.  Sada A.  Thorpe J.R.    A central role for dityrosine crosslinking of amyloid-beta in Alzheimer’s disease Acta Neuropathol. Commun. 2013 1 83 10.1186/2051-5960-1-83 24351276 
69. Caspersen C.  Wang N.  Yao J.  Sosunov A.  Chen X.  Lustbader J.W.  Xu H.W.  Stern D.  McKhann G.  Yan S.D.   Mitochondrial abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease FASEB J. 2005 19 2040 2041 10.1096/fj.05-3735fje 16210396 
70. Crouch P.J.   Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42 J. Neurosci. 2005 25 672 679 10.1523/JNEUROSCI.4276-04.2005 15659604 
71. Devi L.   Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction J. Neurosci. 2006 26 9057 9068 10.1523/JNEUROSCI.1469-06.2006 16943564 
72. Manczak M.  Anekonda T.S.  Henson E.  Park B.S.  Quinn J.  Reddy P.H.   Mitochondria are a direct site of a beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression Hum. Mol. Genet. 2006 15 1437 1449 10.1093/hmg/ddl066 16551656 
73. Casley C.S.  Canevari L.  Land J.M.  Clark J.B.  Sharpe M.A.   beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities J. Neurochem. 2001 80 91 100 10.1046/j.0022-3042.2001.00681.x 
74. Bubber P.  Haroutunian V.  Fisch G.  Blass J.P.  Gibson G.E.   Mitochondrial abnormalities in alzheimer brain: Mechanistic implications Ann. Neurol. 2005 57 695 703 10.1002/ana.20474 15852400 
75. Huang H.-M.  Ou H.-C.  Xu H.  Chen H.-L.  Fowler C.  Gibson G.E.   Inhibition of α-ketoglutarate dehydrogenase complex promotes cytochromec release from mitochondria, caspase-3 activation, and necrotic cell death J. Neurosci. Res. 2003 74 309 317 10.1002/jnr.10756 14515360 
76. Tretter L.  Adam-Vizi V.   Inhibition of krebs cycle enzymes by hydrogen peroxide: A key role of α-ketoglutarate dehydrogenase in limiting nadh production under oxidative stress J. Neurosci. 2000 20 8972 8979 11124972 
77. Li F.  Calingasan N.Y.  Yu F.  Mauck W.M.  Toidze M.  Almeida C.G.  Takahashi R.H.  Carlson G.A.  Flint Beal M.  Lin M.T.    Increased plaque burden in brains of app mutant mnsod heterozygous knockout mice J. Neurochem. 2004 89 1308 1312 10.1111/j.1471-4159.2004.02455.x 15147524 
78. Swerdlow R.H.  Parks J.K.  Cassarino D.S.  Maguire D.J.  Maguire R.S.  Bennett J.P.  Davis R.E.  Parker W.D.   Cybrids in Alzheimer’s disease: A cellular model of the disease? Neurology 1997 49 918 925 10.1212/WNL.49.4.918 9339668 
79. Lustbader J.W.  Cirilli M.  Lin C.  Xu H.W.  Takuma K.  Wang N.  Caspersen C.  Chen X.  Pollak S.  Chaney M.    Abad directly links abeta to mitochondrial toxicity in Alzheimer’s disease Science 2004 304 448 452 10.1126/science.1091230 15087549 
80. Jo D.G.  Arumugam T.V.  Woo H.N.  Park J.S.  Tang S.C.  Mughal M.  Hyun D.H.  Park J.H.  Choi Y.H.  Gwon A.R.    Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer’s disease Neurobiol. Aging 2010 31 917 925 10.1016/j.neurobiolaging.2008.07.003 18687504 
81. Oda A.  Tamaoka A.  Araki W.   Oxidative stress up-regulates presenilin 1 in lipid rafts in neuronal cells J. Neurosci. Res. 2010 88 1137 1145 10.1002/jnr.22271 19885829 
82. Quiroz-Baez R.  Rojas E.  Arias C.   Oxidative stress promotes jnk-dependent amyloidogenic processing of normally expressed human app by differential modification of alpha-, beta- and gamma-secretase expression Neurochem. Int. 2009 55 662 670 10.1016/j.neuint.2009.06.012 19560504 
83. Shen C.  Chen Y.  Liu H.  Zhang K.  Zhang T.  Lin A.  Jing N.   Hydrogen peroxide promotes abeta production through jnk-dependent activation of gamma-secretase J. Biol. Chem. 2008 283 17721 17730 10.1074/jbc.M800013200 18436531 
84. Tamagno E.  Guglielmotto M.  Aragno M.  Borghi R.  Autelli R.  Giliberto L.  Muraca G.  Danni O.  Zhu X.  Smith M.A.    Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein J. Neurochem. 2008 104 683 695 10.1111/j.1471-4159.2007.05072.x 18005001 
85. Tong Y.  Zhou W.  Fung V.  Christensen M.A.  Qing H.  Sun X.  Song W.   Oxidative stress potentiates bace1 gene expression and abeta generation J. Neural Transm. 2004 112 455 469 10.1007/s00702-004-0255-3 15614428 
86. Nunomura A.  Perry G.  Aliev G.  Hirai K.  Takeda A.  Balraj E.K.  Jones P.K.  Ghanbari H.  Wataya T.  Shimohama S.    Oxidative damage is the earliest event in alzheimer disease J. Neuropathol. Exp. Neurol. 2001 60 759 767 10.1093/jnen/60.8.759 11487050 
87. Pratico D.  Uryu K.  Leight S.  Trojanoswki J.Q.  Lee V.M.   Increased lipid peroxidation precedes amyloid plaque formation in an animal model of alzheimer amyloidosis J. Neurosci. 2001 21 4183 4187 11404403 
88. Resende R.  Moreira P.I.  Proença T.  Deshpande A.  Busciglio J.  Pereira C.  Oliveira C.R.   Brain oxidative stress in a triple-transgenic mouse model of alzheimer disease Free Radic. Biol. Med. 2008 44 2051 2057 10.1016/j.freeradbiomed.2008.03.012 18423383 
89. Apelt J.  Bigl M.  Wunderlich P.  Schliebs R.   Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic tg2576 mice with alzheimer-like pathology Int. J. Dev. Neurosci. 2004 22 475 484 10.1016/j.ijdevneu.2004.07.006 15465277 
90. Vitek M.P.  Bhattacharya K.  Glendening J.M.  Stopa E.  Vlassara H.  Bucala R.  Manogue K.  Cerami A.   Advanced glycation end products contribute to amyloidosis in alzheimer disease Proc. Natl. Acad. Sci. USA 1994 91 4766 4770 10.1073/pnas.91.11.4766 8197133 
91. Smith M.A.  Taneda S.  Richey P.L.  Miyata S.  Yan S.D.  Stern D.  Sayre L.M.  Monnier V.M.  Perry G.   Advanced maillard reaction end products are associated with alzheimer disease pathology Proc. Natl. Acad. Sci. USA 1994 91 5710 5714 10.1073/pnas.91.12.5710 8202552 
92. Ledesma M.D.  Bonay P.  Colaco C.  Avila J.   Analysis of microtubule-associated protein tau glycation in paired helical filaments J. Biol. Chem. 1994 269 21614 21619 8063802 
93. Yan S.D.  Yan S.F.  Chen X.  Fu J.  Chen M.  Kuppusamy P.  Smith M.A.  Perry G.  Godman G.C.  Nawroth P.    Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide Nat. Med. 1995 1 693 699 10.1038/nm0795-693 7585153 
94. Liu C.C.  Liu C.C.  Kanekiyo T.  Xu H.  Bu G.   Apolipoprotein e and alzheimer disease: Risk, mechanisms and therapy Nat. Rev. Neurol. 2013 9 106 118 10.1038/nrneurol.2012.263 23296339 
95. Puglielli L.  Tanzi R.E.  Kovacs D.M.   Alzheimer’s disease: The cholesterol connection Nat. Neurosci. 2003 6 345 351 10.1038/nn0403-345 12658281 
96. Sadigh-Eteghad S.  Talebi M.  Farhoudi M.   Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer’s disease. A meta-analysis Neurosciences (Riyadh) 2012 17 321 326 23022896 
97. Bertram L.  Tanzi R.E.   Thirty years of Alzheimer’s disease genetics: The implications of systematic meta-analyses Nat. Neurosci. 2008 9 768 778 10.1038/nrn2494 18802446 
98. Roses A.D.   Apolipoprotein e alleles as risk factors in Alzheimer’s disease Annu. Rev. Med. 1996 47 387 400 10.1146/annurev.med.47.1.387 8712790 
99. Jiang Q.  Lee C.Y.  Mandrekar S.  Wilkinson B.  Cramer P.  Zelcer N.  Mann K.  Lamb B.  Willson T.M.  Collins J.L.    Apoe promotes the proteolytic degradation of abeta Neuron 2008 58 681 693 10.1016/j.neuron.2008.04.010 18549781 
100. Gibson G.E.  Haroutunian V.  Zhang H.  Park L.C.  Shi Q.  Lesser M.  Mohs R.C.  Sheu R.K.  Blass J.P.   Mitochondrial damage in Alzheimer’s disease varies with apolipoprotein e genotype Ann. Neurol. 2000 48 297 303 10.1002/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z 10976635 
101. Puglielli L.  Konopka G.  Pack-Chung E.  Ingano L.A.  Berezovska O.  Hyman B.T.  Chang T.Y.  Tanzi R.E.  Kovacs D.M.   Acyl-coenzyme a: Cholesterol acyltransferase modulates the generation of the amyloid beta-peptide Nat. Cell Biol. 2001 3 905 912 10.1038/ncb1001-905 11584272 
102. Bhattacharyya R.  Kovacs D.M.   Acat inhibition and amyloid beta reduction Biochim. Biophys. Acta 2010 1801 960 965 10.1016/j.bbalip.2010.04.003 20398792 
103. Hutter-Paier B.  Huttunen H.J.  Puglielli L.  Eckman C.B.  Kim D.Y.  Hofmeister A.  Moir R.D.  Domnitz S.B.  Frosch M.P.  Windisch M.    The acat inhibitor cp-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease Neuron 2010 68 1014 10.1016/j.neuron.2010.11.028 
104. Shibuya Y.  Niu Z.  Bryleva E.Y.  Harris B.T.  Murphy S.R.  Kheirollah A.  Bowen Z.D.  Chang C.C.Y.  Chang T.-Y.   Acyl-coenzyme a:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human p301l-tau content at the presymptomatic stage Neurobiol. Aging 2015 36 2248 2259 10.1016/j.neurobiolaging.2015.04.002 25930235 
105. Simons M.  Keller P.  De Strooper B.  Beyreuther K.  Dotti C.G.  Simons K.   Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons Proc. Natl. Acad. Sci. USA 1998 95 6460 6464 10.1073/pnas.95.11.6460 9600988 
106. Aisen P.S.  Davis K.L.  Berg J.D.  Schafer K.  Campbell K.  Thomas R.G.  Weiner M.F.  Farlow M.R.  Sano M.  Grundman M.    A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s disease cooperative study Neurology 2000 54 588 593 10.1212/WNL.54.3.588 10680787 
107. Aisen P.S.  Schafer K.A.  Grundman M.  Pfeiffer E.  Sano M.  Davis K.L.  Farlow M.R.  Jin S.  Thomas R.G.  Thal L.J.    Effects of rofecoxib or naproxen vs placebo on alzheimer disease progression: A randomized controlled trial JAMA 2003 289 2819 2826 10.1001/jama.289.21.2819 12783912 
108. Akiyama H.  Barger S.  Barnum S.  Bradt B.  Bauer J.  Cole G.M.  Cooper N.R.  Eikelenboom P.  Emmerling M.  Fiebich B.L.    Inflammation and Alzheimer’s disease Neurobiol. Aging 2000 21 383 421 10.1016/S0197-4580(00)00124-X 10858586 
109. Blalock E.M.  Chen K.-C.  Stromberg A.J.  Norris C.M.  Kadish I.  Kraner S.D.  Porter N.M.  Landfield P.W.   Harnessing the power of gene microarrays for the study of brain aging and Alzheimer’s disease: Statistical reliability and functional correlation Res. Rev. 2005 4 481 512 10.1016/j.arr.2005.06.006 16257272 
110. Heneka M.T.  Sastre M.  Dumitrescu-Ozimek L.  Dewachter I.  Walter J.  Klockgether T.  Van Leuven F.   Focal glial activation coincides with increased bace1 activation and precedes amyloid plaque deposition in app[v717i] transgenic mice J. Neuroinflamm. 2005 2 22 10.1186/1742-2094-2-22 16212664 
111. Katsel P.L.  Davis K.L.  Haroutunian V.   Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer’s disease Int. Rev. Neurobiol. 2005 41 82 10.1016/s0074-7742(05)63003-6 15797465 
112. Kitazawa M.  Oddo S.  Yamasaki T.R.  Green K.N.  LaFerla F.M.   Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease J. Neurosci. 2005 25 8843 8853 10.1523/JNEUROSCI.2868-05.2005 16192374 
113. Morgan D.  Gordon M.N.  Tan J.  Wilcock D.  Rojiani A.M.   Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for alzheimer therapeutics J. Neuropathol. Exp. Neurol. 2005 64 743 753 10.1097/01.jnen.0000178444.33972.e0 16141783 
114. Reines S.A.  Block G.A.  Morris J.C.  Liu G.  Nessly M.L.  Lines C.R.  Norman B.A.  Baranak C.C.  Rofecoxib Protocol 091 Study Group  Rofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study Neurology 2004 62 66 71 10.1212/WNL.62.1.66 14718699 
115. Szekely C.A.  Thorne J.E.  Zandi P.P.  Ek M.  Messias E.  Breitner J.C.S.  Goodman S.N.   Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: A systematic review Neuroepidemiology 2004 23 159 169 10.1159/000078501 15279021 
116. Van Gool W.A.  Weinstein H.C.  Scheltens P.K.  Walstra G.J.   Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: An 18-month randomised, double-blind, placebo-controlled study Lancet 2001 358 455 460 10.1016/S0140-6736(01)05623-9 11513909 
117. Lee S.  Tong M.  Hang S.  Deochand C.  de la Monte S.   Csf and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer’s disease J. Alzheimers Dis. Parkinsonism 2013 3 128 10.4172/2161-0460.1000128 25035815 
118. Capetillo-Zarate E.  Gracia L.  Yu F.  Banfelder J.R.  Lin M.T.  Tampellini D.  Gouras G.K.   High-resolution 3d reconstruction reveals intra-synaptic amyloid fibrils Am. J. Pathol. 2011 179 2551 2558 10.1016/j.ajpath.2011.07.045 21925470 
119. Blennow K.  Bogdanovic N.  Alafuzoff I.  Ekman R.  Davidsson P.   Synaptic pathology in Alzheimer’s disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the apoe4 allele J. Neural Transm. 1996 103 603 618 10.1007/BF01273157 8811505 
120. DeKosky S.T.  Scheff S.W.   Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity Ann. Neurol. 1990 27 457 464 10.1002/ana.410270502 2360787 
121. Della Sala S.  Parra M.A.  Fabi K.  Luzzi S.  Abrahams S.   Short-term memory binding is impaired in ad but not in non-ad dementias Neuropsychologia 2012 50 833 840 10.1016/j.neuropsychologia.2012.01.018 22289292 
122. Mrak R.E.  Griffin W.S.   Interleukin-1, neuroinflammation, and Alzheimer’s disease Neurobiol. Aging 2001 22 903 908 10.1016/S0197-4580(01)00287-1 11754997 
123. Padmanabhan J.  Levy M.  Dickson D.W.  Potter H.   Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer’s disease brain, induces tau phosphorylation in neurons Brain 2006 129 3020 3034 10.1093/brain/awl255 16987932 
124. Yao Y.  Chinnici C.  Tang H.  Trojanowski J.Q.  Lee V.M.  Pratico D.   Brain inflammation and oxidative stress in a transgenic mouse model of alzheimer-like brain amyloidosis J. Neuroinflamm. 2004 1 21 10.1186/1742-2094-1-21 15500684 
125. Wild-Bode C.  Yamazaki T.  Capell A.  Leimer U.  Steiner H.  Ihara Y.  Haass C.   Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42 J. Biol. Chem. 1997 272 16085 16088 10.1074/jbc.272.26.16085 9195901 
126. Yang A.J.  Chandswangbhuvana D.  Shu T.  Henschen A.  Glabe C.G.   Intracellular accumulation of insoluble, newly synthesized a n-42 in amyloid precursor protein-transfected cells that have been treated with a 1-42 J. Biol. Chem. 1999 274 20650 20656 10.1074/jbc.274.29.20650 10400697 
127. Glabe C.   Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease J. Mol. Neurosci. 2001 17 137 145 10.1385/JMN:17:2:137 11816787 
128. Gouras G.K.  Almeida C.G.  Takahashi R.H.   Intraneuronal abeta accumulation and origin of plaques in Alzheimer’s disease Neurobiol. Aging 2005 26 1235 1244 10.1016/j.neurobiolaging.2005.05.022 16023263 
129. Meyer-Luehmann M.  Coomaraswamy J.  Bolmont T.  Kaeser S.  Schaefer C.  Kilger E.  Neuenschwander A.  Abramowski D.  Frey P.  Jaton A.L.    Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host Science 2006 313 1781 1784 10.1126/science.1131864 16990547 
130. De Strooper B.  Karran E.   The cellular phase of Alzheimer’s disease Cell 2016 164 603 615 10.1016/j.cell.2015.12.056 26871627 
131. Allen N.J.   Astrocyte regulation of synaptic behavior Annu. Rev. Cell Dev. Biol. 2014 30 439 463 10.1146/annurev-cellbio-100913-013053 25288116 
132. Bushong E.A.  Martone M.E.  Jones Y.Z.  Ellisman M.H.   Protoplasmic astrocytes in ca1 stratum radiatum occupy separate anatomical domains J. Neurosci. 2002 22 183 192 11756501 
133. Lian H.  Yang L.  Cole A.  Sun L.  Chiang A.C.-A.  Fowler S.W.  Shim D.J.  Rodriguez-Rivera J.  Taglialatela G.  Jankowsky J.L.    Nfκb-activated astroglial release of complement c3 compromises neuronal morphology and function associated with Alzheimer’s disease Neuron 2015 85 101 115 10.1016/j.neuron.2014.11.018 25533482 
134. Salter M.W.  Beggs S.   Sublime microglia: Expanding roles for the guardians of the cns Cell 2014 158 15 24 10.1016/j.cell.2014.06.008 24995975 
135. Shin R.W.  Iwaki T.  Kitamoto T.  Tateishi J.   Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer’s disease brain tissues Lab. Investig. 1991 64 693 702 1903170 
136. Mawal-Dewan M.  Henley J.  Van de Voorde A.  Trojanowski J.Q.  Lee V.M.   The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases J. Biol. Chem. 1994 269 30981 30987 7983034 
137. Taniguchi T.  Kawamata T.  Mukai H.  Hasegawa H.  Isagawa T.  Yasuda M.  Hashimoto T.  Terashima A.  Nakai M.  Mori H.    Phosphorylation of tau is regulated by pkn J. Biol. Chem. 2001 276 10025 10031 10.1074/jbc.M007427200 11104762 
138. Mandelkow E.M.  Mandelkow E.   Tau in Alzheimer’s disease Trends Cell Biol. 1998 8 425 427 10.1016/S0962-8924(98)01368-3 9854307 
139. Jung H.-J.  Kim Y.-J.  Eggert S.  Chung K.C.  Choi K.S.  Park S.A.   Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62 Exp. Neurol. 2013 248 441 450 10.1016/j.expneurol.2013.07.013 23906983 
140. Eroglu B.  Moskophidis D.  Mivechi N.F.   Loss of hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta Mol. Cell. Biol. 2010 30 4626 4643 10.1128/MCB.01493-09 20679486 
141. Chu J.  Lauretti E.  Pratico D.   Caspase-3-dependent cleavage of akt modulates tau phosphorylation via gsk3beta kinase: Implications for Alzheimer’s disease Mol. Psychiatry 2017 22 1002 1008 10.1038/mp.2016.214 28138159 
142. Tokutake T.  Kasuga K.  Yajima R.  Sekine Y.  Tezuka T.  Nishizawa M.  Ikeuchi T.   Hyperphosphorylation of tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent akt-gsk3beta signaling pathway J. Biol. Chem. 2012 287 35222 35233 10.1074/jbc.M112.348300 22910909 
143. Hernandez F.  Lucas J.J.  Avila J.   Gsk3 and tau: Two convergence points in Alzheimer’s disease J. Alzheimers Dis. 2013 33 Suppl. 1 S141 S144 10.3233/JAD-2012-129025 22710914 
144. Gómez-Ramos A.  Díaz-Nido J.  Smith M.A.  Perry G.  Avila J.   Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells J. Neurosci. Res. 2002 71 863 870 10.1002/jnr.10525 12605413 
145. Su B.  Wang X.  Lee H.  Tabaton M.  Perry G.  Smith M.A.  Zhu X.   Chronic oxidative stress causes increased tau phosphorylation in m17 neuroblastoma cells Neurosci. Lett. 2010 468 267 271 10.1016/j.neulet.2009.11.010 19914335 
146. Sultana R.  Boyd-Kimball D.  Poon H.F.  Cai J.  Pierce W.M.  Klein J.B.  Markesbery W.R.  Zhou X.Z.  Lu K.P.  Butterfield D.A.   Oxidative modification and down-regulation of pin1 in Alzheimer’s disease hippocampus: A redox proteomics analysis Neurobiol. Aging 2006 27 918 925 10.1016/j.neurobiolaging.2005.05.005 15950321 
147. Alonso A.D.C.  Zaidi T.  Novak M.  Grundke-Iqbal I.  Iqbal K.   Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments Proc. Natl. Acad. Sci. USA 2001 98 6923 6928 10.1073/pnas.121119298 11381127 
148. Arriagada P.V.  Growdon J.H.  Hedley-Whyte E.T.  Hyman B.T.   Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease Neurology 1992 42 631 10.1212/WNL.42.3.631 1549228 
149. Ishiki A.  Okamura N.  Furukawa K.  Furumoto S.  Harada R.  Tomita N.  Hiraoka K.  Watanuki S.  Ishikawa Y.  Tago T.    Longitudinal assessment of tau pathology in patients with Alzheimer’s disease using [18f]thk-5117 positron emission tomography PLoS ONE 2015 10 e0140311 10.1371/journal.pone.0140311 26461913 
150. Nelson P.T.  Alafuzoff I.  Bigio E.H.  Bouras C.  Braak H.  Cairns N.J.  Castellani R.J.  Crain B.J.  Davies P.  Del Tredici K.    Correlation of alzheimer disease neuropathologic changes with cognitive status: A review of the literature J. Neuropathol. Exp. Neurol. 2012 71 362 381 10.1097/NEN.0b013e31825018f7 22487856 
151. Hyman B.T.  Marzloff K.  Arriagada P.V.   The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution J. Neuropathol. Exp. Neurol. 1993 52 594 600 10.1097/00005072-199311000-00006 8229078 
152. Herrup K.  Carrillo M.C.  Schenk D.  Cacace A.  Desanti S.  Fremeau R.  Bhat R.  Glicksman M.  May P.  Swerdlow R.    Beyond amyloid: Getting real about nonamyloid targets in Alzheimer’s disease Alzheimers Dement 2013 9 452 458 10.1016/j.jalz.2013.01.017 23809366 
153. Noble W.  Planel E.  Zehr C.  Olm V.  Meyerson J.  Suleman F.  Gaynor K.  Wang L.  LaFrancois J.  Feinstein B.    Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proc. Natl. Acad. Sci. USA 2005 102 6990 6995 10.1073/pnas.0500466102 15867159 
154. Asai M.  Hattori C.  Iwata N.  Saido T.C.  Sasagawa N.  Szabó B.  Hashimoto Y.  Maruyama K.  Tanuma S.  Kiso Y.    The novel beta-secretase inhibitor kmi-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice J. Neurochem. 2006 96 533 540 10.1111/j.1471-4159.2005.03576.x 16336629 
155. Comery T.A.   Acute gamma-secretase inhibition improves contextual fear conditioning in the tg2576 mouse model of Alzheimer’s disease J. Neurosci. 2005 25 8898 8902 10.1523/JNEUROSCI.2693-05.2005 16192379 
156. Schenk D.  Barbour R.  Dunn W.  Gordon G.  Grajeda H.  Guido T.  Hu K.  Huang J.  Johnson-Wood K.  Khan K.    Immunization with amyloid-beta attenuates alzheimer-disease-like pathology in the pdapp mouse Nature 1999 400 173 177 10.1038/22124 10408445 
157. Gravitz L.   Drugs: A tangled web of targets Nature 2011 475 S9 S11 10.1038/475S9a 21760583 
158. Holmes C.  Boche D.  Wilkinson D.  Yadegarfar G.  Hopkins V.  Bayer A.  Jones R.W.  Bullock R.  Love S.  Neal J.W.    Long-term effects of abeta42 immunisation in Alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase i trial Lancet 2008 372 216 223 10.1016/S0140-6736(08)61075-2 18640458 
159. Gilman S.  Koller M.  Black R.S.  Jenkins L.  Griffith S.G.  Fox N.C.  Eisner L.  Kirby L.  Rovira M.B.  Forette F.    Clinical effects of abeta immunization (an1792) in patients with ad in an interrupted trial Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 
160. Orgogozo J.-M.  Gilman S.  Dartigues J.-F.  Laurent B.  Puel M.  Kirby L.C.  Jouanny P.  Dubois B.  Eisner L.  Flitman S.    Subacute meningoencephalitis in a subset of patients with ad after a 42 immunization Neurology 2003 61 46 54 10.1212/01.WNL.0000073623.84147.A8 12847155 
161. Zandi P.P.  Anthony J.C.  Khachaturian A.S.  Stone S.V.  Gustafson D.  Tschanz J.T.  Norton M.C.  Welsh-Bohmer K.A.  Breitner J.C.  Cache County Study Group  Reduced risk of alzheimer disease in users of antioxidant vitamin supplements: The cache county study Arch. Neurol. 2004 61 82 88 10.1001/archneur.61.1.82 14732624 
162. Aisen P.S.  Saumier D.  Briand R.  Laurin J.  Gervais F.  Tremblay P.  Garceau D.   A phase ii study targeting amyloid-beta with 3aps in mild-to-moderate alzheimer disease Neurology 2006 67 1757 1763 10.1212/01.wnl.0000244346.08950.64 17082468 
163. Scharf S.  Mander A.  Ugoni A.  Vajda F.  Christophidis N.   A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease Neurology 1999 53 197 201 10.1212/WNL.53.1.197 10408559 
164. Peng X.  Xing P.  Li X.  Qian Y.  Song F.  Bai Z.  Han G.  Lei H.   Towards personalized intervention for Alzheimer’s disease Genom. Proteom. Bioinf. 2016 14 289 297 10.1016/j.gpb.2016.01.006 27693548 
165. Tartaglia G.G.  Pawar A.P.  Campioni S.  Dobson C.M.  Chiti F.  Vendruscolo M.   Prediction of aggregation-prone regions in structured proteins J. Mol. Biol. 2008 380 425 436 10.1016/j.jmb.2008.05.013 18514226 
166. Trainor K.  Broom A.  Meiering E.M.   Exploring the relationships between protein sequence, structure and solubility Curr. Opin. Struct. Biol. 2017 42 136 146 10.1016/j.sbi.2017.01.004 28160724 
167. Arosio P.  Vendruscolo M.  Dobson C.M.  Knowles T.P.J.   Chemical kinetics for drug discovery to combat protein aggregation diseases Trends Pharmacol. Sci. 2014 35 127 135 10.1016/j.tips.2013.12.005 24560688 
168. Goyal D.  Shuaib S.  Mann S.  Goyal B.   Rationally designed peptides and peptidomimetics as inhibitors of amyloid-beta (abeta) aggregation: Potential therapeutics of Alzheimer’s disease ACS Comb. Sci. 2017 19 55 80 10.1021/acscombsci.6b00116 28045249 
169. Chen R.P.Y.   From nose to brain: The promise of peptide therapy for Alzheimer’s disease and other neurodegenerative diseases J. Alzheimers Dis. Parkinsonism 2017 7 10.4172/2161-0460.1000314 
170. Unger J.  Livingston J.  Moss A.   Insulin receptors in the central nervous system: Localization, signalling mechanisms and functional aspects Prog. Neurobiol. 1991 36 343 362 10.1016/0301-0082(91)90015-S 1887067 
171. Zhao W.-Q.  Alkon D.L.   Role of insulin and insulin receptor in learning and memory Mol. Cell. Endocrinol. 2001 177 125 134 10.1016/S0303-7207(01)00455-5 11377828 
172. Gluck M.A.  Mercado E.  Myers C.E.   Learning and Memory: From Brain to Behavior 2nd ed. Worth Publishers New York, NY, USA 2014 xxiii, 497 
173. Ito R.  Lee A.C.H.   The role of the hippocampus in approach-avoidance conflict decision-making: Evidence from rodent and human studies Behav. Brain Res. 2016 313 345 357 10.1016/j.bbr.2016.07.039 27457133 
174. Moser E.I.  Kropff E.  Moser M.B.   Place cells, grid cells, and the brain’s spatial representation system Annu. Rev. Neurosci. 2008 31 69 89 10.1146/annurev.neuro.31.061307.090723 18284371 
175. De Felice F.G.  Vieira M.N.  Bomfim T.R.  Decker H.  Velasco P.T.  Lambert M.P.  Viola K.L.  Zhao W.Q.  Ferreira S.T.  Klein W.L.   Protection of synapses against alzheimer’s-linked toxins: Insulin signaling prevents the pathogenic binding of abeta oligomers Proc. Natl. Acad. Sci. USA 2009 106 1971 1976 10.1073/pnas.0809158106 19188609 
176. Zhao W.-Q.  De Felice F.G.  Fernandez S.  Chen H.  Lambert M.P.  Quon M.J.  Krafft G.A.  Klein W.L.   Amyloid beta oligomers induce impairment of neuronal insulin receptors FASEB J. 2007 22 246 260 10.1096/fj.06-7703com 17720802 
177. Francis G.J.  Martinez J.A.  Liu W.Q.  Xu K.  Ayer A.  Fine J.  Tuor U.I.  Glazner G.  Hanson L.R.  Frey W.H. 2nd    Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy Brain 2008 131 3311 3334 10.1093/brain/awn288 19015157 
178. Haj-ali V.  Mohaddes G.  Babri S.H.   Intracerebroventricular insulin improves spatial learning and memory in male wistar rats Behav. Neurosci. 2009 123 1309 1314 10.1037/a0017722 20001114 
179. Zhao W.-Q.  Chen H.  Quon M.J.  Alkon D.L.   Insulin and the insulin receptor in experimental models of learning and memory Eur. J. Pharmacol. 2004 490 71 81 10.1016/j.ejphar.2004.02.045 15094074 
180. Benedict C.  Hallschmid M.  Hatke A.  Schultes B.  Fehm H.L.  Born J.  Kern W.   Intranasal insulin improves memory in humans Psychoneuroendocrinology 2004 29 1326 1334 10.1016/j.psyneuen.2004.04.003 15288712 
181. Benedict C.  Kern W.  Schultes B.  Born J.  Hallschmid M.   Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin J. Clin. Endocrinol. Metab. 2008 93 1339 1344 10.1210/jc.2007-2606 18230654 
182. Krug R.  Benedict C.  Born J.  Hallschmid M.   Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory J. Clin. Endocrinol. Metab. 2010 95 E468 E472 10.1210/jc.2010-0744 20719831 
183. Reger M.A.  Watson G.S.  Frey W.H.  Baker L.D.  Cholerton B.  Keeling M.L.  Belongia D.A.  Fishel M.A.  Plymate S.R.  Schellenberg G.D.    Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by apoe genotype Neurobiol. Aging 2006 27 451 458 10.1016/j.neurobiolaging.2005.03.016 15964100 
184. Benedict C.  Hallschmid M.  Schmitz K.  Schultes B.  Ratter F.  Fehm H.L.  Born J.  Kern W.   Intranasal insulin improves memory in humans: Superiority of insulin aspart Neuropsychopharmacology 2006 32 239 243 10.1038/sj.npp.1301193 16936707 
185. Pandini G.  Pace V.  Copani A.  Squatrito S.  Milardi D.  Vigneri R.   Insulin has multiple antiamyloidogenic effects on human neuronal cells Endocrinology 2013 154 375 387 10.1210/en.2012-1661 23239816 
186. Zheng W.-H.  Kar S.  Doré S.  Quirion R.   Insulin-like growth factor-1 (igf-1): A neuroprotective trophic factor acting via the akt kinase pathway Adv. Res. Neurodegener. 2000 261 272 10.1007/978-3-7091-6301-6_17 
187. Watson G.S.  Peskind E.R.  Asthana S.  Purganan K.  Wait C.  Chapman D.  Schwartz M.W.  Plymate S.  Craft S.   Insulin increases csf abeta42 levels in normal older adults Neurology 2003 60 1899 1903 10.1212/01.WNL.0000065916.25128.25 12821730 
188. Claxton A.  Baker L.D.  Hanson A.  Trittschuh E.H.  Cholerton B.  Morgan A.  Callaghan M.  Arbuckle M.  Behl C.  Craft S.   Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia J. Alzheimers Dis. 2015 44 897 906 10.3233/JAD-141791 25374101 
189. Craft S.  Baker L.D.  Montine T.J.  Minoshima S.  Watson G.S.  Claxton A.  Arbuckle M.  Callaghan M.  Tsai E.  Plymate S.R.    Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial Arch. Neurol. 2012 69 29 38 10.1001/archneurol.2011.233 21911655 
190. Messier C.  Teutenberg K.   The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer’s disease Neural Plast. 2005 12 311 328 10.1155/NP.2005.311 16444902 
191. Reger M.A.  Watson G.S.  Green P.S.  Baker L.D.  Cholerton B.  Fishel M.A.  Plymate S.R.  Cherrier M.M.  Schellenberg G.D.  Frey W.H. 2nd    Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults J. Alzheimers Dis. 2008 13 323 331 10.3233/JAD-2008-13309 18430999 
192. Watson G.S.  Bernhardt T.  Reger M.A.  Cholerton B.A.  Baker L.D.  Peskind E.R.  Asthana S.  Plymate S.R.  Frolich L.  Craft S.   Insulin effects on csf norepinephrine and cognition in Alzheimer’s disease Neurobiol. Aging 2006 27 38 41 10.1016/j.neurobiolaging.2004.11.011 16298239 
193. Galasko D.   Insulin and Alzheimer’s disease: An amyloid connection Neurology 2003 60 1886 1887 10.1212/WNL.60.12.1886 12821727 
194. Tarassishin L.  Yin Y.I.  Bassit B.  Li Y.M.   Processing of notch and amyloid precursor protein by gamma-secretase is spatially distinct Proc. Natl. Acad. Sci. USA 2004 101 17050 17055 10.1073/pnas.0408007101 15563588 
195. Van Es J.H.  van Gijn M.E.  Riccio O.  van den Born M.  Vooijs M.  Begthel H.  Cozijnsen M.  Robine S.  Winton D.J.  Radtke F.    Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells Nature 2005 435 959 963 10.1038/nature03659 15959515 
196. Citron M.   Alzheimer’s disease: Strategies for disease modification Nat. Rev. Drug Discov. 2010 9 387 398 10.1038/nrd2896 20431570 
197. Opar A.   Mixed results for disease-modification strategies for Alzheimer’s disease Nat. Rev. Drug Discov. 2008 7 717 718 10.1038/nrd2676 19172684 
198. Menting K.W.  Claassen J.A.   Beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease Front. Aging Neurosci. 2014 6 165 10.3389/fnagi.2014.00165 25100992 
199. Wolfe M.S.   Gamma-secretase as a target for Alzheimer’s disease Adv. Pharmacol. 2012 64 127 153 10.1016/B978-0-12-394816-8.00004-0 22840746 
200. Evin G.  Lessene G.  Wilkins S.   Bace inhibitors as potential drugs for the treatment of Alzheimer’s disease: Focus on bioactivity Recent Pat. CNS Drug Discov. 2011 6 91 106 10.2174/157488911795933938 21585329 
201. Vincent B.  Govitrapong P.   Activation of the alpha-secretase processing of abetapp as a therapeutic approach in Alzheimer’s disease J. Alzheimers Dis. 2011 24 Suppl. 2 75 94 10.3233/JAD-2011-110218 21422515 
202. Coric V.  Salloway S.  van Dyck C.  Kerselaers W.  Kaplita S.  Curtis C.  Ross J.  Richter R.W.  Andreasen N.  Brody M.    A phase ii study of the gamma-secretase inhibitor avagacestat (bms-708163) in predementia Alzheimer’s disease Alzheimers Dement. J. Alzheimers Assoc. 2013 9 283 10.1016/j.jalz.2013.05.569 
203. Coric V.  van Dyck C.H.  Salloway S.  Andreasen N.  Brody M.  Richter R.W.  Soininen H.  Thein S.  Shiovitz T.  Pilcher G.    Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate alzheimer disease Arch. Neurol. 2012 69 1430 1440 10.1001/archneurol.2012.2194 22892585 
204. Doody R.S.  Raman R.  Farlow M.  Iwatsubo T.  Vellas B.  Joffe S.  Kieburtz K.  He F.  Sun X.  Thomas R.G.    A phase 3 trial of semagacestat for treatment of Alzheimer’s disease N. Engl. J. Med. 2013 369 341 350 10.1056/NEJMoa1210951 23883379 
205. Green R.C.   Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients with Mild Alzheimer Disease: A Randomized Controlled Trial JAMA 2009 302 2557 2564 10.1001/jama.2009.1866 20009055 
206. May P.C.  Willis B.A.  Lowe S.L.  Dean R.A.  Monk S.A.  Cocke P.J.  Audia J.E.  Boggs L.N.  Borders A.R.  Brier R.A.    The potent bace1 inhibitor ly2886721 elicits robust central abeta pharmacodynamic responses in mice, dogs, and humans J. Neurosci. 2015 35 1199 1210 10.1523/JNEUROSCI.4129-14.2015 25609634 
207. Huang W.  Wei W.  Shen Z.   Drug-like chelating agents: A potential lead for Alzheimer’s disease RSC Adv. 2014 4 52088 52099 10.1039/C4RA09193K 
208. Kepp K.P.   Bioinorganic chemistry of Alzheimer’s disease Chem. Rev. 2012 112 5193 5239 10.1021/cr300009x 22793492 
209. Lannfelt L.  Blennow K.  Zetterberg H.  Batsman S.  Ames D.  Harrison J.  Masters C.L.  Targum S.  Bush A.I.  Murdoch R.    Safety, efficacy, and biomarker findings of pbt2 in targeting abeta as a modifying therapy for Alzheimer’s disease: A phase iia, double-blind, randomised, placebo-controlled trial Lancet Neurol. 2008 7 779 786 10.1016/S1474-4422(08)70167-4 18672400 
210. Ritchie C.W.  Bush A.I.  Mackinnon A.  Macfarlane S.  Mastwyk M.  MacGregor L.  Kiers L.  Cherny R.  Li Q.-X.  Tammer A.    Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting abeta amyloid deposition and toxicity in alzheimer disease Arch. Neurol. 2003 60 1685 1691 10.1001/archneur.60.12.1685 14676042 
211. Boutajangout A.  Wisniewski T.   Tau-based therapeutic approaches for Alzheimer’s disease—A mini-review Gerontology 2014 60 381 385 10.1159/000358875 24732638 
212. Gotz J.  Ittner A.  Ittner L.M.   Tau-targeted treatment strategies in Alzheimer’s disease Br. J. Pharmacol. 2012 165 1246 1259 10.1111/j.1476-5381.2011.01713.x 22044248 
213. Navarrete L.P.  Perez P.  Morales I.  Maccioni R.B.   Novel drugs affecting tau behavior in the treatment of Alzheimer’s disease and tauopathies Curr. Alzheimer Res. 2011 8 678 685 10.2174/156720511796717122 21605038 
214. Safety and Efficacy Study Evaluating TRx0237 in Subjects with Mild Alzheimer’s Disease Available online: https://clinicaltrials.gov/ct2/show/NCT01689233  (accessed on 29 January 2018) 
215. Doody R.S.  Thomas R.G.  Farlow M.  Iwatsubo T.  Vellas B.  Joffe S.  Kieburtz K.  Raman R.  Sun X.  Aisen P.S.    Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease N. Engl. J. Med. 2014 370 311 321 10.1056/NEJMoa1312889 24450890 
216. Ladiwala A.R.  Bhattacharya M.  Perchiacca J.M.  Cao P.  Raleigh D.P.  Abedini A.  Schmidt A.M.  Varkey J.  Langen R.  Tessier P.M.   Rational design of potent domain antibody inhibitors of amyloid fibril assembly Proc. Natl. Acad. Sci. USA 2012 109 19965 19970 10.1073/pnas.1208797109 23161913 
217. Liu E.  Schmidt M.E.  Margolin R.  Sperling R.  Koeppe R.  Mason N.S.  Klunk W.E.  Mathis C.A.  Salloway S.  Fox N.C.    Amyloid-beta 11 c-pib-pet imaging results from 2 randomized bapineuzumab phase 3 ad trials Neurology 2015 85 692 700 10.1212/WNL.0000000000001877 26208959 
218. Salloway S.  Sperling R.  Fox N.C.  Blennow K.  Klunk W.  Raskind M.  Sabbagh M.  Honig L.S.  Porsteinsson A.P.  Ferris S.    Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease N. Engl. J. Med. 2014 370 322 333 10.1056/NEJMoa1304839 24450891 
219. Wang Q.  Yu X.  Li L.  Zheng J.   Inhibition of amyloid-beta aggregation in Alzheimer’s disease Curr. Pharm. Des. 2014 20 1223 1243 10.2174/13816128113199990068 23713775 
220. Estrada L.D.  Soto C.   Disrupting beta-amyloid aggregation for alzheimer disease treatment Curr. Top. Med. Chem. 2007 7 115 126 10.2174/156802607779318262 17266599 
221. Liu R.  Su R.  Liang M.  Huang R.  Wang M.  Qi W.  He Z.   Physicochemical strategies for inhibition of amyloid fibril formation: An overview of recent advances Curr. Med. Chem. 2012 19 4157 4174 10.2174/092986712802430018 22830338 
222. Dasilva K.A.  Shaw J.E.  McLaurin J.   Amyloid-beta fibrillogenesis: Structural insight and therapeutic intervention Exp. Neurol. 2010 223 311 321 10.1016/j.expneurol.2009.08.032 19744483 
223. Karran E.  Mercken M.  Strooper B.D.   The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics Nat. Rev. Drug Discov. 2011 10 698 712 10.1038/nrd3505 21852788 
224. Mishra P.  Ayyannan S.R.  Panda G.   Perspectives on inhibiting beta-amyloid aggregation through structure-based drug design Chem. Med. Chem. 2015 10 1467 1474 10.1002/cmdc.201500215 26230674 
225. Jones S.  Thornton J.M.   Principles of protein-protein interactions Proc. Natl. Acad. Sci. USA 1996 93 13 20 10.1073/pnas.93.1.13 8552589 
226. Keskin O.  Gursoy A.  Ma B.  Nussinov R.   Principles of Protein−Protein Interactions: What are the Preferred Ways for Proteins to Interact? Chem. Rev. 2008 108 1225 1244 10.1021/cr040409x 18355092 
227. Cheng A.C.  Coleman R.G.  Smyth K.T.  Cao Q.  Soulard P.  Caffrey D.R.  Salzberg A.C.  Huang E.S.   Structure-based maximal affinity model predicts small-molecule druggability Nat. Biotechnol. 2007 25 71 75 10.1038/nbt1273 17211405 
228. Smith R.D.  Hu L.  Falkner J.A.  Benson M.L.  Nerothin J.P.  Carlson H.A.   Exploring protein–ligand recognition with binding moad J. Mol. Graph. Model. 2006 24 414 425 10.1016/j.jmgm.2005.08.002 16168689 
229. Wells J.A.  McClendon C.L.   Reaching for high-hanging fruit in drug discovery at protein–protein interfaces Nature 2007 450 1001 1009 10.1038/nature06526 18075579 
230. Hambly K.  Danzer J.  Muskal S.  Debe D.A.   Interrogating the druggable genome with structural informatics Mol. Divers. 2006 10 273 281 10.1007/s11030-006-9035-3 17031532 
231. Gestwicki J.E.  Crabtree G.R.  Graef I.A.   Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation Science 2004 306 865 869 10.1126/science.1101262 15514157 
232. Gardberg A.S.  Dice L.T.  Ou S.  Rich R.L.  Helmbrecht E.  Ko J.  Wetzel R.  Myszka D.G.  Patterson P.H.  Dealwis C.   Molecular basis for passive immunotherapy of Alzheimer’s disease Proc. Natl. Acad. Sci. USA 2007 104 15659 15664 10.1073/pnas.0705888104 17895381 
233. McLaurin J.  Cecal R.  Kierstead M.E.  Tian X.  Phinney A.L.  Manea M.  French J.E.  Lambermon M.H.L.  Darabie A.A.  Brown M.E.    Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis Nat. Med. 2002 8 1263 1269 10.1038/nm790 12379850 
234. Huang S.-H.  Ke S.-C.  Lin T.-H.  Huang H.-B.  Chen Y.-C.   Effect of c-terminal residues of abeta on copper binding affinity, structural conversion and aggregation PLoS ONE 2014 9 e90385 10.1371/journal.pone.0090385 24594588 
235. Lazo N.D.  Grant M.A.  Condron M.C.  Rigby A.C.  Teplow D.B.   On the nucleation of amyloid beta-protein monomer folding Protein Sci. 2009 14 1581 1596 10.1110/ps.041292205 15930005 
236. Petkova A.T.  Ishii Y.  Balbach J.J.  Antzutkin O.N.  Leapman R.D.  Delaglio F.  Tycko R.   A structural model for alzheimer’s beta-amyloid fibrils based on experimental constraints from solid state nmr Proc. Natl. Acad. Sci. USA 2002 99 16742 16747 10.1073/pnas.262663499 12481027 
237. Wälti M.A.  Ravotti F.  Arai H.  Glabe C.G.  Wall J.S.  Böckmann A.  Güntert P.  Meier B.H.  Riek R.   Atomic-resolution structure of a disease-relevant abeta(1–42) amyloid fibril Proc. Nat. Acad. Sci. USA 2016 113 E4976 E4984 10.1073/pnas.1600749113 27469165 
238. Wasmer C.  Lange A.  Van Melckebeke H.  Siemer A.B.  Riek R.  Meier B.H.   Amyloid fibrils of the het-s(218-289) prion form a beta solenoid with a triangular hydrophobic core Science 2008 319 1523 1526 10.1126/science.1151839 18339938 
239. Xu S.   Aggregation drives “misfolding” in protein amyloid fiber formation Amyloid 2007 14 119 131 10.1080/13506120701260059 17577685 
240. Yang M.  Lei M.  Yordanov B.  Huo S.   Peptide plane can flip in two opposite directions: Implication in amyloid formation of transthyretin J. Phys. Chem. B 2006 110 5829 5833 10.1021/jp0570420 16553385 
241. Milner-White J.E.  Watson J.D.  Qi G.  Hayward S.   Amyloid formation may involve α- to beta sheet interconversion via peptide plane flipping Structure 2006 14 1369 1376 10.1016/j.str.2006.06.016 16962968 
242. Hayward S.  Milner-White E.J.   The geometry of alpha-sheet: Implications for its possible function as amyloid precursor in proteins Proteins 2008 71 415 425 10.1002/prot.21717 17957773 
243. Grillo-Bosch D.  Carulla N.  Cruz M.  Sánchez L.  Pujol-Pina R.  Madurga S.  Rabanal F.  Giralt E.   Retro-enantio N -methylated peptides as beta-amyloid aggregation inhibitors Chem. Med. Chem. 2009 4 1488 1494 10.1002/cmdc.200900191 19591190 
244. Doig A.J.  Derreumaux P.   Inhibition of protein aggregation and amyloid formation by small molecules Curr. Opin. Struct. Biol. 2015 30 50 56 10.1016/j.sbi.2014.12.004 25559306 
245. Lu J.-X.  Qiang W.  Yau W.-M.  Schwieters C.D.  Meredith S.C.  Tycko R.   Molecular structure of beta-amyloid fibrils in Alzheimer’s disease brain tissue Cell 2013 154 1257 1268 10.1016/j.cell.2013.08.035 24034249 
246. Nguyen P.  Derreumaux P.   Understanding amyloid fibril nucleation and abeta oligomer/drug interactions from computer simulations Acc. Chem. Res. 2014 47 603 611 10.1021/ar4002075 24368046 
247. Lesné S.E.  Sherman M.A.  Grant M.  Kuskowski M.  Schneider J.A.  Bennett D.A.  Ashe K.H.   Brain amyloid-beta oligomers in ageing and Alzheimer’s disease Brain 2013 136 1383 1398 10.1093/brain/awt062 23576130 
248. Nussbaum J.M.  Schilling S.  Cynis H.  Silva A.  Swanson E.  Wangsanut T.  Tayler K.  Wiltgen B.  Hatami A.  Ronicke R.    Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta Nature 2012 485 651 655 10.1038/nature11060 22660329 
249. Estrada L.D.  Lasagna C.  Soto C.   Design of inhibitors of amyloid-beta misfolding and aggregation for alzheimer’s therapy Pharmacological Mechanisms in Alzheimer’s Therapeutics Springer New York, NY, USA 2007 238 254 
250. Amijee H.  Madine J.  Middleton D.A.  Doig A.J.   Inhibitors of protein aggregation and toxicity Biochem. Soc. Trans. 2009 37 692 696 10.1042/BST0370692 19614577 
251. Nerelius C.  Sandegren A.  Sargsyan H.  Raunak R.  Leijonmarck H.  Chatterjee U.  Fisahn A.  Imarisio S.  Lomas D.A.  Crowther D.C.    Alpha-helix targeting reduces amyloid-beta peptide toxicity Proc. Natl. Acad. Sci. USA 2009 106 9191 9196 10.1073/pnas.0810364106 19458258 
252. Yan L.-M.  Velkova A.  Tatarek-Nossol M.  Rammes G.  Sibaev A.  Andreetto E.  Kracklauer M.  Bakou M.  Malideli E.  Göke B.    Selectively N -methylated soluble iapp mimics as potent iapp receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both iapp and abeta40 Angew. Chem. Int. Ed. 2013 52 10378 10383 10.1002/anie.201302840 23956012 
253. Loureiro J.A.  Crespo R.  Börner H.  Martins P.M.  Rocha F.A.  Coelho M.  Pereira M.C.  Rocha S.   Fluorinated beta-sheet breaker peptides J. Mater. Chem. B 2014 2 2259 2264 10.1039/C3TB21483D 
254. Francioso A.  Punzi P.  Boffi A.  Lori C.  Martire S.  Giordano C.  D’Erme M.  Mosca L.   beta-sheet interfering molecules acting against beta-amyloid aggregation and fibrillogenesis Biorgan. Med. Chem. 2015 23 1671 1683 10.1016/j.bmc.2015.02.041 25769517 
255. Jagota S.  Rajadas J.   Synthesis of d-amino acid peptides and their effect on beta-amyloid aggregation and toxicity in transgenic caenorhabditis elegans Med. Chem. Res. 2012 22 3991 4000 10.1007/s00044-012-0386-2 
256. Chorev M.  Goodman M.   Recent developments in retro peptides and proteins—An ongoing topochemical exploration Trends Biotechnol. 1995 13 438 445 10.1016/S0167-7799(00)88999-4 7546569 
257. Fletcher M.D.  Campbell M.M.   Partially modified retro-inverso peptides: Development, synthesis, and conformational behavior Chem. Rev. 1998 98 763 796 10.1021/cr970468t 11848914 
258. Mason J.M.   Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention Future Med. Chem. 2010 2 1813 1822 10.4155/fmc.10.259 21428804 
259. Matharu B.  El-Agnaf O.  Razvi A.  Austen B.M.   Development of retro-inverso peptides as anti-aggregation drugs for beta-amyloid in Alzheimer’s disease Peptides 2010 31 1866 1872 10.1016/j.peptides.2010.06.033 20633587 
260. Parthsarathy V.  McClean P.L.  Hölscher C.  Taylor M.  Tinker C.  Jones G.  Kolosov O.  Salvati E.  Gregori M.  Masserini M.    A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the appswe/ps1Δe9 mouse model of Alzheimer’s disease PLoS ONE 2013 8 e54769 10.1371/annotation/57e0a947-8600-4658-b04c-cf7a45c8bd8d 23382963 
261. Taylor M.  Moore S.  Mayes J.  Parkin E.  Beeg M.  Canovi M.  Gobbi M.  Mann D.M.A.  Allsop D.   Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer’s disease Biochemistry 2010 49 3261 3272 10.1021/bi100144m 20230062 
262. Wiesehan K.  Buder K.  Linke R.P.  Patt S.  Stoldt M.  Unger E.  Schmitt B.  Bucci E.  Willbold D.   Selection of d-amino-acid peptides that bind to Alzheimer’s disease amyloid peptide abeta1-42 by mirror image phage display ChemBioChem 2003 4 748 753 10.1002/cbic.200300631 12898626 
263. Arai T.  Araya T.  Sasaki D.  Taniguchi A.  Sato T.  Sohma Y.  Kanai M.   Rational design and identification of a non-peptidic aggregation inhibitor of amyloid-beta based on a pharmacophore motif obtained from cyclo[-lys-leu-val-phe-phe-] Angew. Chem. Int. Ed. Engl. 2014 53 8236 8239 10.1002/anie.201405109 24931598 
264. Luo J.  Abrahams J.P.   Cyclic peptides as inhibitors of amyloid fibrillation Chemistry 2014 20 2410 2419 10.1002/chem.201304253 24478167 
265. Amijee H.  Bate C.  Williams A.  Virdee J.  Jeggo R.  Spanswick D.  Scopes D.I.C.  Treherne J.M.  Mazzitelli S.  Chawner R.    The N -methylated peptide sen304 powerfully inhibits abeta(1–42) toxicity by perturbing oligomer formation Biochemistry 2012 51 8338 8352 10.1021/bi300415v 23025847 
266. O’Hare E.  Scopes D.I.C.  Kim E.-M.  Palmer P.  Spanswick D.  McMahon B.  Amijee H.  Nerou E.  Treherne J.M.  Jeggo R.   Novel 5-aryloxypyrimidine sen1576 as a candidate for the treatment of Alzheimer’s disease Int. J. Neuropsychopharmacol. 2013 17 117 126 10.1017/S1461145713000886 24103729 
267. Hopping G.  Kellock J.  Barnwal R.P.  Law P.  Bryers J.  Varani G.  Caughey B.  Daggett V.   Designed α-sheet peptides inhibit amyloid formation by targeting toxic oligomers Elife 2014 3 e01681 10.7554/eLife.01681 25027691 
268. Ashur-Fabian O.  Segal-Ruder Y.  Skutelsky E.  Brenneman D.E.  Steingart R.A.  Giladi E.  Gozes I.   The neuroprotective peptide nap inhibits the aggregation of the beta-amyloid peptide Peptides 2003 24 1413 1423 10.1016/j.peptides.2003.08.005 14706557 
269. Aloisi A.  Barca A.  Romano A.  Guerrieri S.  Storelli C.  Rinaldi R.  Verri T.   Anti-aggregating effect of the naturally occurring dipeptide carnosine on abeta1-42 fibril formation PLoS ONE 2013 8 e68159 10.1371/journal.pone.0068159 23844165 
270. Herculano B.  Tamura M.  Ohba A.  Shimatani M.  Kutsuna N.  Hisatsune T.   Beta-alanyl-l-histidine rescues cognitive deficits caused by feeding a high fat diet in a transgenic mouse model of Alzheimer’s disease J. Alzheimers Dis. 2013 33 983 997 10.3233/JAD-2012-121324 23099816 
271. Wang Q.  Liang G.  Zhang M.  Zhao J.  Patel K.  Yu X.  Zhao C.  Ding B.  Zhang G.  Zhou F.    De novo design of self-assembled hexapeptides as beta-amyloid (abeta) peptide inhibitors ACS Chem. Neurosci. 2014 5 972 981 10.1021/cn500165s 25133634 
272. Gozes I.  Morimoto B.H.  Tiong J.  Fox A.  Sutherland K.  Dangoor D.  Holser-Cochav M.  Vered K.  Newton P.  Aisen P.S.    Nap: Research and development of a peptide derived from activity-dependent neuroprotective protein (adnp) CNS Drug Rev. 2006 11 353 368 10.1111/j.1527-3458.2005.tb00053.x 
273. Matsuoka Y.  Jouroukhin Y.  Gray A.J.  Ma L.  Hirata-Fukae C.  Li H.-F.  Feng L.  Lecanu L.  Walker B.R.  Planel E.    A neuronal microtubule-interacting agent, napvsipq, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease J. Pharmacol. Exp. Ther. 2008 325 146 153 10.1124/jpet.107.130526 18199809 
274. Handattu S.P.  Garber D.W.  Monroe C.E.  van Groen T.  Kadish I.  Nayyar G.  Cao D.  Palgunachari M.N.  Li L.  Anantharamaiah G.M.   Oral apolipoprotein a-i mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer’s disease Neurobiol. Dis. 2009 34 525 534 10.1016/j.nbd.2009.03.007 19344763 
275. Yamin G.  Ruchala P.  Teplow D.B.   A peptide hairpin inhibitor of amyloid beta-protein oligomerization and fibrillogenesis Biochemistry 2009 48 11329 11331 10.1021/bi901325g 19877710 
276. Fink A.L.   Protein aggregation: Folding aggregates, inclusion bodies and amyloid Fold Des. 1998 3 R9 R23 10.1016/S1359-0278(98)00002-9 9502314 
277. Manning M.C.  Chou D.K.  Murphy B.M.  Payne R.W.  Katayama D.S.   Stability of protein pharmaceuticals: An update Pharm. Res. 2010 27 544 575 10.1007/s11095-009-0045-6 20143256 
278. Frokjaer S.  Otzen D.E.   Protein drug stability: A formulation challenge Nat. Rev. Drug Discov. 2005 4 298 306 10.1038/nrd1695 15803194 
279. Chiti F.  Stefani M.  Taddei N.  Ramponi G.  Dobson C.M.   Rationalization of the effects of mutations on peptide and protein aggregation rates Nature 2003 424 805 808 10.1038/nature01891 12917692 
280. DuBay K.F.  Pawar A.P.  Chiti F.  Zurdo J.  Dobson C.M.  Vendruscolo M.   Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains J. Mol. Biol. 2004 341 1317 1326 10.1016/j.jmb.2004.06.043 15302561 
281. Chiti F.  Taddei N.  Baroni F.  Capanni C.  Stefani M.  Ramponi G.  Dobson C.M.   Kinetic partitioning of protein folding and aggregation Nat. Struct. Biol. 2002 9 137 143 10.1038/nsb752 11799398 
282. Fernandez-Escamilla A.-M.  Rousseau F.  Schymkowitz J.  Serrano L.   Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins Nat. Biotechnol. 2004 22 1302 1306 10.1038/nbt1012 15361882 
283. Krishnan R.  Lindquist S.L.   Structural insights into a yeast prion illuminate nucleation and strain diversity Nature 2005 435 765 772 10.1038/nature03679 15944694 
284. Meinhardt J.  Tartaglia G.G.  Pawar A.  Christopeit T.  Hortschansky P.  Schroeckh V.  Dobson C.M.  Vendruscolo M.  Fändrich M.   Similarities in the thermodynamics and kinetics of aggregation of disease-related abeta(1-40) peptides Protein Sci. 2007 16 1214 1222 10.1110/ps.062734207 17525469 
285. Pawar A.P.  DuBay K.F.  Zurdo J.  Chiti F.  Vendruscolo M.  Dobson C.M.   Prediction of “aggregation-prone” and “aggregation-susceptible” regions in proteins associated with neurodegenerative diseases J. Mol. Biol. 2005 350 379 392 10.1016/j.jmb.2005.04.016 15925383 
286. Sanchez de Groot N.  Pallares I.  Aviles F.X.  Vendrell J.  Ventura S.   Prediction of “hot spots” of aggregation in disease-linked polypeptides BMC Struct. Biol. 2005 5 18 10.1186/1472-6807-5-18 16197548 
287. Sawaya M.R.  Sambashivan S.  Nelson R.  Ivanova M.I.  Sievers S.A.  Apostol M.I.  Thompson M.J.  Balbirnie M.  Wiltzius J.J.W.  McFarlane H.T.    Atomic structures of amyloid cross-beta spines reveal varied steric zippers Nature 2007 447 453 457 10.1038/nature05695 17468747 
288. Williams A.D.  Portelius E.  Kheterpal I.  Guo J.  Cook K.D.  Xu Y.  Wetzel R.   Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis J. Mol. Biol. 2004 335 833 842 10.1016/j.jmb.2003.11.008 14687578 
289. Chalifour R.J.  McLaughlin R.W.  Lavoie L.  Morissette C.  Tremblay N.  Boule M.  Sarazin P.  Stea D.  Lacombe D.  Tremblay P.    Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide J. Biol. Chem. 2003 278 34874 34881 10.1074/jbc.M212694200 12840031 
290. Soto C.  Sigurdsson E.M.  Morelli L.  Asok Kumar R.  Castaño E.M.  Frangione B.   beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for alzheimer’s therapy Nat. Med. 1998 4 822 826 10.1038/nm0798-822 9662374 
291. Tatarek-Nossol M.  Yan L.-M.  Schmauder A.  Tenidis K.  Westermark G.  Kapurniotu A.   Inhibition of hiapp amyloid-fibril formation and apoptotic cell death by a designed hiapp amyloid- core-containing hexapeptide Chem. Biol. 2005 12 797 809 10.1016/j.chembiol.2005.05.010 16039527 
292. Luhrs T.  Ritter C.  Adrian M.  Riek-Loher D.  Bohrmann B.  Dobeli H.  Schubert D.  Riek R.   3D structure of alzheimer’s amyloid-β (1-42) fibrils Proc. Natl. Acad. Sci. USA 2005 102 17342 17347 10.1073/pnas.0506723102 16293696 
293. Petkova A.T.  Yau W.-M.  Tycko R.   Experimental constraints on quaternary structure in alzheimer’s beta-amyloid fibrils Biochemistry 2006 45 498 512 10.1021/bi051952q 16401079 
294. Agostini F.  Vendruscolo M.  Tartaglia G.G.   Sequence-based prediction of protein solubility J. Mol. Biol. 2012 421 237 241 10.1016/j.jmb.2011.12.005 22172487 
295. Huang H.L.  Charoenkwan P.  Kao T.F.  Lee H.C.  Chang F.L.  Huang W.L.  Ho S.J.  Shu L.S.  Chen W.L.  Ho S.Y.   Prediction and analysis of protein solubility using a novel scoring card method with dipeptide composition BMC Bioinform. 2012 13 Suppl. 17 S3 10.1186/1471-2105-13-S17-S3 
296. Niu X.H.  Shi F.  Hu X.H.  Xia J.B.  Li N.N.   Predicting the protein solubility by integrating chaos games representation and entropy in information theory Exp. Syst. Appl. 2014 41 1672 1679 10.1016/j.eswa.2013.08.064 
297. Samak T.  Gunter D.  Wang Z.   Prediction of protein solubility in E. coli  Proceedings of the 2012 IEEE 8th International Conference on E-Science (e-Science) Chicago, IL, USA 8–12 October 2012 Curran Associates Red Hook, NY, USA 2013 178 185 
298. Smialowski P.  Doose G.  Torkler P.  Kaufmann S.  Frishman D.   Proso ii—A new method for protein solubility prediction FEBS J. 2012 279 2192 2200 10.1111/j.1742-4658.2012.08603.x 22536855 
299. Yang Y.  Niroula A.  Shen B.  Vihinen M.   Pon-sol: Prediction of effects of amino acid substitutions on protein solubility Bioinformatics 2016 32 2032 2034 10.1093/bioinformatics/btw066 27153720 
300. Chou K.C.   Prediction of protein cellular attributes using pseudo-amino acid composition Proteins 2001 43 246 255 10.1002/prot.1035 11288174 
301. Conchillo-Solé O.  de Groot N.S.  Avilés F.X.  Vendrell J.  Daura X.  Ventura S.   Aggrescan: A server for the prediction and evaluation of “hot spots” of aggregation in polypeptides BMC Bioinform. 2007 8 65 10.1186/1471-2105-8-65 17324296 
302. Du J.  Cho P.Y.  Yang D.T.  Murphy R.M.   Identification of beta-amyloid-binding sites on transthyretin Protein Eng. Des. Sel. 2012 25 337 345 10.1093/protein/gzs026 22670059 
303. Ganesan A.  Siekierska A.  Beerten J.  Brams M.  Van Durme J.  De Baets G.  Van der Kant R.  Gallardo R.  Ramakers M.  Langenberg T.    Structural hot spots for the solubility of globular proteins Nat. Commun. 2016 7 10816 10.1038/ncomms10816 26905391 
304. Garbuzynskiy S.O.  Lobanov M.Y.  Galzitskaya O.V.   Foldamyloid: A method of prediction of amyloidogenic regions from protein sequence Bioinformatics 2009 26 326 332 10.1093/bioinformatics/btp691 20019059 
305. Gasior P.  Kotulska M.   Fish amyloid—A new method for finding amyloidogenic segments in proteins based on site specific co-occurence of aminoacids BMC Bioinform. 2014 15 54 10.1186/1471-2105-15-54 24564523 
306. Hirose S.  Noguchi T.   Espresso: A system for estimating protein expression and solubility in protein expression systems Proteomics 2013 13 1444 1456 10.1002/pmic.201200175 23436767 
307. Maurer-Stroh S.  Debulpaep M.  Kuemmerer N.  de la Paz M.L.  Martins I.C.  Reumers J.  Morris K.L.  Copland A.  Serpell L.  Serrano L.    Corrigendum: Exploring the sequence determinants of amyloid structure using position-specific scoring matrices Nat. Methods 2010 7 855 10.1038/nmeth1010-855a 
308. Navarro S.  Villar-Pique A.  Ventura S.   Selection against toxic aggregation-prone protein sequences in bacteria BBA-Mol. Cell Res. 2014 1843 866 874 10.1016/j.bbamcr.2014.01.020 24472658 
309. Neudecker P.  Robustelli P.  Cavalli A.  Walsh P.  Lundstrom P.  Zarrine-Afsar A.  Sharpe S.  Vendruscolo M.  Kay L.E.   Structure of an intermediate state in protein folding and aggregation Science 2012 336 362 366 10.1126/science.1214203 22517863 
310. O’Donnell C.W.  Waldispuhl J.  Lis M.  Halfmann R.  Devadas S.  Lindquist S.  Berger B.   A method for probing the mutational landscape of amyloid structure Bioinformatics 2011 27 I34 I42 10.1093/bioinformatics/btr238 21685090 
311. Perchiacca J.M.  Bhattacharya M.  Tessier P.M.   Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions Proteins Struct. Funct. Bioinform. 2011 79 2637 2647 10.1002/prot.23085 21732420 
312. Sahin E.  Jordan J.L.  Spatara M.L.  Naranjo A.  Costanzo J.A.  Weiss W.F.  Robinson A.S.  Fernandez E.J.  Roberts C.J.   Computational design and biophysical characterization of aggregation-resistant point mutations for gamma d crystallin illustrate a balance of conformational stability and intrinsic aggregation propensity Biochemistry 2011 50 628 639 10.1021/bi100978r 21184609 
313. Sormanni P.  Aprile F.A.  Vendruscolo M.   The camsol method of rational design of protein mutants with enhanced solubility J. Mol. Biol. 2015 427 478 490 10.1016/j.jmb.2014.09.026 25451785 
314. Thompson M.J.  Sievers S.A.  Karanicolas J.  Ivanova M.I.  Baker D.  Eisenberg D.   The 3D profile method for identifying fibril-forming segments of proteins Proc. Natl. Acad. Sci. USA 2006 103 4074 4078 10.1073/pnas.0511295103 16537487 
315. Trovato A.  Seno F.  Tosatto S.C.E.   The pasta server for protein aggregation prediction Protein Eng. Des. Sel. 2007 20 521 523 10.1093/protein/gzm042 17720750 
316. Villar-Pique A.  de Groot N.S.  Sabaté R.  Acebrón S.P.  Celaya G.  Fernàndez-Busquets X.  Muga A.  Ventura S.   The effect of amyloidogenic peptides on bacterial aging correlates with their intrinsic aggregation propensity J. Mol. Biol. 2012 421 270 281 10.1016/j.jmb.2011.12.014 22200483 
317. Walsh I.  Seno F.  Tosatto S.C.E.  Trovato A.   Pasta 2.0: An improved server for protein aggregation prediction Nucleic Acids Res. 2014 42 W301 W307 10.1093/nar/gku399 24848016 
318. Bryan A.W.  O’Donnell C.W.  Menke M.  Cowen L.J.  Lindquist S.  Berger B.   Stitcher: Dynamic assembly of likely amyloid and prion beta-structures from secondary structure predictions Proteins Struct. Funct. Bioinform. 2011 80 410 420 10.1002/prot.23203 22095906 
319. Chiti F.  Dobson C.M.   Amyloid formation by globular proteins under native conditions Nat. Chem. Biol. 2009 5 15 22 10.1038/nchembio.131 19088715 
320. Trainor K.  Gingras Z.  Shillingford C.  Malakian H.  Gosselin M.  Lipovsek D.  Meiering E.M.   Ensemble modeling and intracellular aggregation of an engineered immunoglobulin-like domain J. Mol. Biol. 2016 428 1365 1374 10.1016/j.jmb.2016.02.016 26903090 
321. Wetzel R.   Mutations and off-pathway aggregation of proteins Trends Biotechnol. 1994 12 193 198 10.1016/0167-7799(94)90082-5 7764903 
322. Chan P.  Curtis R.A.  Warwicker J.   Soluble expression of proteins correlates with a lack of positively-charged surface Sci. Rep. 2013 3 3333 10.1038/srep03333 24276756 
323. Chennamsetty N.  Voynov V.  Kayser V.  Helk B.  Trout B.L.   Design of therapeutic proteins with enhanced stability Proc. Natl. Acad. Sci. USA 2009 106 11937 11942 10.1073/pnas.0904191106 19571001 
324. Schaller A.  Connors N.K.  Oelmeier S.A.  Hubbuch J.  Middelberg A.P.J.   Predicting recombinant protein expression experiments using molecular dynamics simulation Chem. Eng. Sci. 2015 121 340 350 10.1016/j.ces.2014.09.044 
325. Zambrano R.  Jamroz M.  Szczasiuk A.  Pujols J.  Kmiecik S.  Ventura S.   Aggrescan3D (A3D): Server for prediction of aggregation properties of protein structures Nucleic Acids Res. 2015 43 W306 W313 10.1093/nar/gkv359 25883144 
326. Tiwari M.K.  Kepp K.P.   Modeling the aggregation propensity and toxicity of amyloid-beta variants J. Alzheimers Dis. 2015 47 215 229 10.3233/JAD-150046 26402770 
327. Tanaka M.  Collins S.R.  Toyama B.H.  Weissman J.S.   The physical basis of how prion conformations determine strain phenotypes Nature 2006 442 585 589 10.1038/nature04922 16810177 
328. Cohen S.I.A.  Vendruscolo M.  Dobson C.M.  Knowles T.P.J.   Nucleated polymerization with secondary pathways. III. Equilibrium behavior and oligomer populations J. Chem. Phys. 2011 135 065107 10.1063/1.3608918 21842956 
329. Bishop M.F.  Ferrone F.A.   Kinetics of nucleation-controlled polymerization. A perturbation treatment for use with a secondary pathway Biophys. J. 1984 46 631 644 10.1016/S0006-3495(84)84062-X 6498276 
330. Knowles T.P.J.  Waudby C.A.  Devlin G.L.  Cohen S.I.A.  Aguzzi A.  Vendruscolo M.  Terentjev E.M.  Welland M.E.  Dobson C.M.   An analytical solution to the kinetics of breakable filament assembly Science 2009 326 1533 1537 10.1126/science.1178250 20007899 
331. Cohen S.I.A.  Vendruscolo M.  Dobson C.M.  Knowles T.P.J.   From macroscopic measurements to microscopic mechanisms of protein aggregation J. Mol. Biol. 2012 421 160 171 10.1016/j.jmb.2012.02.031 22406275 
332. Feng B.Y.  Toyama B.H.  Wille H.  Colby D.W.  Collins S.R.  May B.C.H.  Prusiner S.B.  Weissman J.  Shoichet B.K.   Small-molecule aggregates inhibit amyloid polymerization Nat. Chem. Biol. 2008 4 197 199 10.1038/nchembio.65 18223646 
333. Lendel C.  Bolognesi B.  Wahlström A.  Dobson C.M.  Gräslund A.   Detergent-like interaction of congo red with the amyloid beta peptide Biochemistry 2010 49 1358 1360 10.1021/bi902005t 20070125 
334. Abelein A.  Lang L.  Lendel C.  Gräslund A.  Danielsson J.   Transient small molecule interactions kinetically modulate amyloid beta peptide self-assembly FEBS Lett. 2012 586 3991 3995 10.1016/j.febslet.2012.09.035 23058290 
335. Buell A.K.  Dobson C.M.  Knowles T.P.J.  Welland M.E.   Interactions between amyloidophilic dyes and their relevance to studies of amyloid inhibitors Biophys. J. 2010 99 3492 3497 10.1016/j.bpj.2010.08.074 21081099 
336. Buell A.K.  Esbjorner E.K.  Riss P.J.  White D.A.  Aigbirhio F.I.  Toth G.  Welland M.E.  Dobson C.M.  Knowles T.P.   Probing small molecule binding to amyloid fibrils Phys. Chem. Chem. Phys. 2011 13 20044 20052 10.1039/c1cp22283j 22006124 
337. Cabaleiro-Lago C.  Quinlan-Pluck F.  Lynch I.  Lindman S.  Minogue A.M.  Thulin E.  Walsh D.M.  Dawson K.A.  Linse S.   Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles J. Am. Chem. Soc. 2008 130 15437 15443 10.1021/ja8041806 18954050 
338. Shammas S.L.  Waudby C.A.  Wang S.  Buell A.K.  Knowles T.P.J.  Ecroyd H.  Welland M.E.  Carver J.A.  Dobson C.M.  Meehan S.   Binding of the molecular chaperone αb-crystallin to abeta amyloid fibrils inhibits fibril elongation Biophys. J. 2011 101 1681 1689 10.1016/j.bpj.2011.07.056 21961594 
339. Woods L.A.  Platt G.W.  Hellewell A.L.  Hewitt E.W.  Homans S.W.  Ashcroft A.E.  Radford S.E.   Ligand binding to distinct states diverts aggregation of an amyloid-forming protein Nat. Chem. Biol. 2011 7 730 739 10.1038/nchembio.635 21873994 
340. Cohen S.I.A.  Linse S.  Luheshi L.M.  Hellstrand E.  White D.A.  Rajah L.  Otzen D.E.  Vendruscolo M.  Dobson C.M.  Knowles T.P.J.   Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism Proc. Natl. Acad. Sci. USA 2013 110 9758 9763 10.1073/pnas.1218402110 23703910 
341. Xu L.Q.  Wu S.  Buell A.K.  Cohen S.I.  Chen L.J.  Hu W.H.  Cusack S.A.  Itzhaki L.S.  Zhang H.  Knowles T.P.    Influence of specific hsp70 domains on fibril formation of the yeast prion protein Ure2 Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013 368 20110410 10.1098/rstb.2011.0410 23530260 
342. Cukalevski R.  Lundqvist M.  Oslakovic C.  Dahlbäck B.  Linse S.  Cedervall T.   Structural changes in apolipoproteins bound to nanoparticles Langmuir 2011 27 14360 14369 10.1021/la203290a 21978381 
343. Meng X.  Munishkina L.A.  Fink A.L.  Uversky V.N.   Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation Biochemistry 2009 48 8206 8224 10.1021/bi900506b 19634918 
344. Ehrnhoefer D.E.  Bieschke J.  Boeddrich A.  Herbst M.  Masino L.  Lurz R.  Engemann S.  Pastore A.  Wanker E.E.   Egcg redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 2008 15 558 566 10.1038/nsmb.1437 18511942 
345. Ladiwala A.R.A.  Dordick J.S.  Tessier P.M.   Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways J. Biol. Chem. 2010 286 3209 3218 10.1074/jbc.M110.173856 21098486 
346. Kumar A.  Moody L.  Olaivar J.F.  Lewis N.A.  Khade R.L.  Holder A.A.  Zhang Y.  Rangachari V.   Inhibition of abeta42 peptide aggregation by a binuclear ruthenium(ii)−platinum(ii) complex: Potential for multimetal organometallics as anti-amyloid agents ACS Chem. Neurosci. 2010 1 691 701 10.1021/cn100046m 21221412 
347. Yoo S.I.  Yang M.  Brender J.R.  Subramanian V.  Sun K.  Joo N.E.  Jeong S.-H.  Ramamoorthy A.  Kotov N.A.   Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: Functional similarities with proteins Angew. Chem. Int. Ed. 2011 50 5110 5115 10.1002/anie.201007824 21495130 
348. Zhang H.  Xu L.-Q.  Perrett S.   Studying the effects of chaperones on amyloid fibril formation Methods 2011 53 285 294 10.1016/j.ymeth.2010.11.009 21144901 
349. Juhasz G.  Marki A.  Vass G.  Fulop L.  Budai D.  Penke B.  Falkay G.  Szegedi V.   An intraperitoneally administered pentapeptide protects against abeta (1-42) induced neuronal excitation in vivo J. Alzheimers Dis. 2009 16 189 196 10.3233/JAD-2009-0947 19158435 
350. Chacón M.A.  Barría M.I.  Soto C.  Inestrosa N.C.   beta-sheet breaker peptide prevents abeta-induced spatial memory impairments with partial reduction of amyloid deposits Mol. Psychiatry 2004 9 953 961 10.1038/sj.mp.4001516 15098004 
351. Frydman-Marom A.  Rechter M.  Shefler I.  Bram Y.  Shalev D.E.  Gazit E.   Cognitive-performance recovery of Alzheimer’s disease model mice by modulation of early soluble amyloidal assemblies Angew. Chem. 2009 48 1981 1986 10.1002/anie.200802123 19035593 
352. Permanne B.  Adessi C.  Saborio G.P.  Fraga S.  Frossard M.J.  Van Dorpe J.  Dewachter I.  Banks W.A.  Van Leuven F.  Soto C.   Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer’s disease by treatment with a beta-sheet breaker peptide FASEB J. 2002 16 860 862 10.1096/fj.01-0841fje 11967228 
353. Van Groen T.  Kadish I.  Funke A.  Bartnik D.  Willbold D.   Treatment with abeta42 binding d-amino acid peptides reduce amyloid deposition and inflammation in app/ps1 double transgenic mice Adv. Protein Chem. Struct. Biol. 2012 133 152 10.1016/b978-0-12-398314-5.00005-2 22814708 
354. Van Groen T.  Wiesehan K.  Funke S.A.  Kadish I.  Nagel-Steger L.  Willbold D.   Reduction of Alzheimer’s disease amyloid plaque load in transgenic mice by D3, a D-enantiomeric peptide identified by mirror image phage display Chem. Med. Chem. 2008 3 1848 1852 10.1002/cmdc.200800273 19016284 
355. Shukla V.  Zheng Y.-L.  Mishra S.K.  Amin N.D.  Steiner J.  Grant P.  Kesavapany S.  Pant H.C.   A truncated peptide from p35, a cdk5 activator, prevents Alzheimer’s disease phenotypes in model mice FASEB J. 2012 27 174 186 10.1096/fj.12-217497 23038754 
356. Aileen Funke S.  van Groen T.  Kadish I.  Bartnik D.  Nagel-Steger L.  Brener O.  Sehl T.  Batra-Safferling R.  Moriscot C.  Schoehn G.    Oral treatment with thed-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer’s disease transgenic mice ACS Chem. Neurosci. 2010 1 639 648 10.1021/cn100057j 22778851 
357. Meredith M.E.  Salameh T.S.  Banks W.A.   Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases AAPS J. 2015 17 780 787 10.1208/s12248-015-9719-7 25801717 
358. Rangasamy S.B.  Corbett G.T.  Roy A.  Modi K.K.  Bennett D.A.  Mufson E.J.  Ghosh S.  Pahan K.   Intranasal delivery of nemo-binding domain peptide prevents memory loss in a mouse model of Alzheimer’s disease J. Alzheimers Dis. 2015 47 385 402 10.3233/JAD-150040 26401561 
359. Cheng Y.S.  Chen Z.T.  Liao T.Y.  Lin C.  Shen H.C.  Wang Y.H.  Chang C.W.  Liu R.S.  Chen R.P.  Tu P.H.   An intranasally delivered peptide drug ameliorates cognitive decline in alzheimer transgenic mice EMBO Mol. Med. 2017 9 703 715 10.15252/emmm.201606666 28356312 
360. Rat D.  Schmitt U.  Tippmann F.  Dewachter I.  Theunis C.  Wieczerzak E.  Postina R.  van Leuven F.  Fahrenholz F.  Kojro E.   Neuropeptide pituitary adenylate cyclase-activating polypeptide (pacap) slows down Alzheimer’s disease-like pathology in amyloid precursor protein-transgenic mice FASEB J. 2011 25 3208 3218 10.1096/fj.10-180133 21593432 
361. Matsuoka Y.  Gray A.J.  Hirata-Fukae C.  Minami S.S.  Waterhouse E.G.  Mattson M.P.  LaFerla F.M.  Gozes I.  Aisen P.S.   Intranasal nap administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stage J. Mol. Neurosci. 2007 31 165 170 17478890 
362. Reger M.A.  Watson G.S.  Green P.S.  Wilkinson C.W.  Baker L.D.  Cholerton B.  Fishel M.A.  Plymate S.R.  Breitner J.C.  DeGroodt W.    Intranasal insulin improves cognition and modulates beta-amyloid in early ad Neurology 2008 70 440 448 10.1212/01.WNL.0000265401.62434.36 17942819 
363. Dhamoon M.S.  Noble J.M.  Craft S.   Intranasal insulin improves cognition and modulates beta-amyloid in early ad Neurology 2009 72 292 294 292–293; author reply 293–294 10.1212/01.wnl.0000344246.91081.2c 19153380 
364. Schiöth H.B.  Craft S.  Brooks S.J.  Frey W.H.  Benedict C.   Brain insulin signaling and Alzheimer’s disease: Current evidence and future directions Mol. Neurobiol. 2011 46 4 10 10.1007/s12035-011-8229-6 22205300 
365. Shemesh E.  Rudich A.  Harman-Boehm I.  Cukierman-Yaffe T.   Effect of intranasal insulin on cognitive function: A systematic review J. Clin. Endocrinol. Metab. 2012 97 366 376 10.1210/jc.2011-1802 22162476 
366. Kapurniotu A.  Buck A.  Weber M.  Schmauder A.  Hirsch T.  Bernhagen J.  Tatarek-Nossol M.   Conformational restriction via cyclization in beta-amyloid peptide abeta(1-28) leads to an inhibitor of abeta(1-28) amyloidogenesis and cytotoxicity Chem. Biol. 2003 10 149 159 10.1016/S1074-5521(03)00022-X 12618187

